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LIST OF ABBREVIATIONS 
 
AD: Alzheimer’s disease  
ALS: amyotrophic lateral sclerosis  
BSE: bovine spongiform encephalopathy  
CC1: positively charged cluster 1 
CC2: positively charged cluster 2 
CJD: Creutzfeldt-Jakob disease  
CMA: chaperone-mediated autophagy 
CtmPrP: PrP with the C-terminus facing the ER 
CWD: chronic wasting disease  
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ER: endoplasmic reticulum 
ERAD: endoplasmic reticulum associated degradation  
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FTD: frontotemporal dementia  
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HD: Huntington’s disease 
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HEK293: human embryonic kidney 293 cell line 
HSC: hematopoietic stem cells  
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HSP: heat shock protein 
Hsp70: heat-shock protein 70 
IDP: intrinsically disordered proteins  
IPOD: insoluble protein deposit  
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KO N2a: N2a cell line knock-out for PrPC  
LAMP2: lysosome-associated membrane protein type 2 
MAVS: mitochondrial antiviral signalling protein  
MNDs: motor neuron diseases  
MTOC: microtubule organizing centre 
MVB: multivesicular body 
MVBs: endosomal multivesicular bodies 
ND: neurodegenerative disease 
NtmPrP: PrP with the C-terminus facing the cytosol 
PD: Parkinson’s disease 
PK: proteinase-K 
PrPC: cellular prion protein  
PrPC1: N-terminally truncated PrP fragment anchored to the plasma membrane  
PrP-CAA: prion protein cerebral amyloid angiopathy  
PrPN1: secreted N-terminally truncated PrP fragment 
PrPres: protease-resistant prion protein  
PrPSc: Scrapie PrP 
PS1: presenilin 1 
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RLRs: RIG-1 like receptors 
ROS: reactive oxygen species  
RRM: RNA recognition motif 
SBMA: spinobulbar muscular atrophy 
ScN2a: Scrapie infected N2a cell line 
secPrP: secreted PrP  
SG: stress granule 
SOD: superoxide dismutase  
STI1: stress inducible protein 1 
SUMO2: small ubiquitin-like modifier 2 
TCR: T-cell receptor 
TGN: trans Golgi network  
TME: transmissible mink encephalopathy  
TRAF6: Tumor necrosis factor receptor (TNFR)-associated factor 6  
TSE: transmissible spongiform encephalopathy 
Ub: Ubiquitin 
UBDs: Ub binding domains  
vCJD: variant Creutzfeldt-Jakob disease 
WT N2a: N2a cell line wild type for PrPC 
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ABSTRACT 
Prion diseases are characterized by the spreading and the accumulation of the 
pathological isoform (PrPSc) of the cellular prion protein (PrPC). Accumulation of 
PrPSc in the brain results in loss of neurons, astrogliosis, PrP amyloid plaques and 
spongiform degeneration of the tissue. Despite many advances in the study of 
neurodegeneration caused by prions, knowledge about the physiological function of 
the PrPC is still lacking. It is well established that the absence of PrPC rescues the 
toxic effect of prions. A neuroprotective function of PrPC as well as a role in cell 
signalling has been suggested. Ubiquitylation is a cellular process to address 
proteins to different fates, e.g. degradation, aggregation, localization, DNA damage 
repair. It is known that PrPC is ubiquitylated via the canonical ubiquitin code and 
addressed to proteasomal degradation. In this work we investigated the 
relationship between PrPC and the Tumor necrosis factor receptor (TNFR)-
associated factor 6 (TRAF6), a player of the atypical ubiquitylation that drives 
ubiquitylated substrates to a different cellular fate. TRAF6 ubiquitylates α-synuclein 
and huntingtin as well as their pathological isoforms. TRAF6 is found in cellular 
aggregates of these proteins. Through in vitro and in vivo experiments we found 
that full-length and cytosolic form of PrPC are able to interact with TRAF6 and are 
present in cellular aggregates. Moreover, full-length PrPC is a substrate of TRAF6 
ubiquitylation. These findings open the door to the identification of a putative 
common mechanism for neurodegenerative diseases, suggesting a role for TRAF6 in 
regulating the fate of PrPC and of other neurodegenerative-associated proteins. 
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CHAPTER 1 
INTRODUCTION 
Neurodegenerative diseases are an age-dependent leading cause of death, 
characterized by the progressive loss of nerve cells and affecting movement or 
mental functions. With the increase in life expectancy, the number of affected 
persons is strikingly increased but yet no disease-modifying therapies exist. Because 
of their enormous social and economic implications, neurodegenerative diseases  
are considered a public health priority. 
Neurodegenerative diseases include Alzheimer’s disease (AD), Parkinson’s disease 
(PD), Huntington’s disease (HD), frontotemporal dementia (FTD) and motor neuron 
diseases (MNDs) [e.g., amyotrophic lateral sclerosis (ALS)]. Each disease is 
characterized by the progressive dysfunction of specific neural populations, 
associated with extra and intracellular accumulation of misfolded proteins. The 
clinical manifestations associated to each diseases depend on the anatomical 
location of the affected neurons and on the nature of the unfolded protein (Figure 
1). 
 
Figure 1. Protein aggregates in neurodegenerative diseases. (a) Senile plaques in neocortex of AD. 
(b) Neuro fibrillary tangles in the hippocampus of FTD. (c) Lewy body in Substantia Nigra of PD. (d) 
Intranuclear polyglutamine inclusion in neocortex of HD. (e) Ubiquitylated inclusion in spinal cord 
motor neuron of ALS. (f) Protease-resistant PrP in cerebellum of Creutzfeldt-Jacob disease (CJD). 
(Forman, Trojanowski et al. 2004). 
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At the cellular level, abnormal protein dynamics have to be referred to altered post-
translational modification of newly synthesized proteins, deficiency of the ubiquitin-
proteasome-autophagy system, oxidative stress, mitochondrial dysfunction, 
compromised axonal transport (Jellinger 2010). An overlap of neurodegenerative 
diseases and intraindividual phenotypic diversities have been recently observed, 
suggesting a synergistic mechanisms between pathological proteins and common 
pathogenic mechanisms (Fujishiro, Tsuboi et al. 2008, Clarimon, Molina-Porcel et al. 
2009). 
Appearance of neurodegenerative diseases is mainly attributed to genetic 
alterations; however, most causes are of unknown or sporadic origin.  The discovery 
of prions has provided an explanation of how a disease can be both infectious and 
genetic (Prusiner 1993). Neurodegenerative diseases can be now classified as 
‘‘protein misfolding’’ diseases (Gregersen 2006, Winderickx, Delay et al. 2008) or 
proteinopathies (Forman, Trojanowski et al. 2004, Forman, Trojanowski et al. 2007) 
(Figure 2). 
 
Figure 2. Classification of neurodegenerative diseases with protein deposits (proteinopathies) 
(Jellinger 2010). 
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PRION DISEASES  
Prion diseases, also termed transmissible spongiform encephalopathies (TSEs) are a 
group of fatal neurodegenerative diseases that affects both humans and animals. 
They represent an heterogeneous group of brain disorders. Prion diseases include 
genetic, transmitted and sporadic forms and display a wide spectrum of clinical 
phenotypes and histopathological patterns. Human TSEs include Creutzfeldt-Jakob 
disease (CJD), Gerstmann-Strӓussler-Scheinker syndrome (GSS), kuru, fatal familial 
insomnia (FFI) and prion protein cerebral amyloid angiopathy (PrP-CAA). Animal 
TSEs include the most known Scrapie of sheep and goats and the bovine spongiform 
encephalopathy (BSE) of cattle, the chronic wasting disease (CWD) of elks and 
deers, the feline spongiform encephalopathy (FSE) of cats, the transmissible mink 
encephalopathy (TME) of minks and the exotic ungulate encephalopathy (EUE) of 
nyala and kudu (Table 1). 
 
Table 1. List of prion diseases of human and animals. Adapted from (Prusiner, 2001) 
 
DISEASE HOST MECHANISM OF PATHOGENESIS* 
Kuru Fore people in 
New Guinea 
Infection through ritualistic cannibalism 
Creutzfeldt-Jakob disease Humans Infection from prion-contaminated human 
growth hormone, dura mater grafts, and so forth 
New variant Humans Infection from bovine prions? 
Familial Humans Germ-line mutations in the PrP gene 
Sporadic Humans Somatic mutation or spontaneous conversion of 
PrPC into PrPSc?  
Gerstmann-Strӓussler-
Scheinker disease 
Humans Germ-line mutations in the PrP gene 
Fatal familial insomnia Humans Germ-line mutations in the PrP gene (D178N, 
M129) 
Sporadic fatal insomnia Humans Somatic mutation or spontaneous conversion of 
PrPC into PrPSc? 
Scrapie Sheep Infection in genetically susceptible sheep 
Bovine spongiform 
encephalopathy 
Cattle Infection with prion-contaminated meat and 
bone meal  
Transmissible mink 
encephalopathy 
Mink Infection with prions from sheep or cattle 
Chronic wasting disease Mule deer, elk Unknown 
Feline spongiform 
encephalopathy 
Cats Infection with prion-contaminated beef 
Exotic ungulate 
encephalopathy 
Greater kudu, 
nyala, oryx 
Infection with prion-contaminated meat and 
bone meal 
*A question mark indicates that mechanism has not been confirmed. PrP denotes prion protein. 
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The sporadic, infectious and many of the genetically determined human as well as 
animal forms of prion diseases can be transmitted across and within animal species. 
The underlying mechanism of all TSEs involves changes in the conformation of the 
cellular prion protein (PrPC) into a pathogenic PrP conformer (named Scrapie PrP, 
PrPSc), which is capable of converting other PrPC  molecules into the abnormal form. 
Conversion in PrPSc results in a degenerative cascade, with the potential to transmit 
the disease (Prusiner 1998). Clinical manifestations of TSEs in humans include 
ataxia, dementia, insomnia, deviant behaviour, paraplegia and paresthesias. These 
symptoms are determined by a plethora of neuropathological changes rather than 
by specific and definite features, as they range from minimal to widespread 
astrocytic gliosis, neuronal loss, PrP amyloid plaques and vacuolation (spongiform 
appearance of brain tissue) (Soto and Satani 2011). Spongiform vacuolation, which 
is the most consistent histological abnormality to describe this group of disorders, 
can vary from focal areas of micro-vacuolation to areas of extensive confluent 
spongiform changes in the cerebral cortex, frequently observed also in the basal 
ganglia and thalamus in sporadic CJD, or from plaques with a margin of radiating 
fibrils in Kuru to ‘florid’ plaques in variant CJD (vCJD) in the occipital cortex and 
cerebellum (Parchi, Giese et al. 1999, Ironside, Head et al. 2002). However, 
vacuolation is not a diagnostic feature sufficient in the diagnosis of GSS , the 
neuropathology of which varies from absence of spongiform changes to deposits of 
fibrillar and non-fibrillar PrP in the cerebral and cerebellar parenchyma (Ghetti, 
Piccardo et al. 1996).  
Besides the different conformation of vacuoles, the morphology of PrP deposits as 
well as the affected brain regions depend on the polymorphisms of the PRNP gene 
and the specific genetic mutation involved. Moreover, the prion strain and the host 
also contributes to the variability observed prion diseases. 
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Figure 3. Multiple neurodegenerative pathways are implicated in TSEs. Neuropathological features 
of infected brains include the accumulation of PrP
Sc 
deposits, synaptic damage and dendrite loss, 
spongiform degeneration, astroglial activation and neuronal death. (Soto and Satani 2011). 
 
THE PRION CONCEPT 
The transmissibility of TSEs was accidentally demonstrated in 1937, after the 
inoculation of a Scottish sheep with a brain extract tissue against a common virus. 
The inoculum contained infectious material as the 10% of the flock developed 
scrapie. The transmission was subsequently demonstrated to sheep and mice 
(Chandler 1961). In humans, an infectious route was firstly demonstrated for Kuru 
in the cannibalistic tribes of New Guinea and confirmed in pioneering studies of 
transmission in chimpanzee (Gajdusek, Gibbs et al. 1966). The same observations 
were obtained for CJD (Gibbs, Gajdusek et al. 1968) and GSS (Masters, Gajdusek et 
al. 1981). In 1967, Alper and colleagues demonstrated that the agent causing TSEs 
was extremely resistant to nucleic acid inactivation, thus excluding a virus or viroid 
as infectious pathogens (Alper, Cramp et al. 1967). In the same year, J.S. Griffith 
speculated for the first time that the causative agent could be a protein (Griffith 
1967). This launch the so-called ‘protein-only’ hypothesis of TSE propagation. The 
’protein-only hypothesis’ has challenged the central dogma of biology. In fact, 
according to the new hypothesis, proteins themselves (and not only DNA and RNA) 
could store and propagate biological information. The term “prion” was 
subsequently introduced by Stanley B. Prusiner in 1982. “Prion” stands for 
“proteinaceous infectious particle”, to underline the exclusively proteinaceous 
property of this infective agent as primary cause of prion diseases (Prusiner 1982). 
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Isolation of the protease-resistant prion protein (PrPres) as a 27-30 kDa resistant 
fragment allowed the determination of its amino-terminal sequence leading to the 
identification of an endogenous cellular gene (Prnp in mouse chromosome 2 or 
PRNP in human chromosome 20), whose translational product was called PrPC 
(Chesebro, Race et al. 1985, Oesch, Westaway et al. 1985, Basler, Oesch et al. 1986). 
PrPC was proven to be the product of a single host gene, present endogenously and 
constitutively expressed by many cell types. The conversion of PrPC into its 
protease-resistant disease-associated form, named PrP Scrapie (PrPSc), is the result 
of a post-translational conformational change. In fact, the α-helical content of the 
PrPC diminishes at the expense of an increase of β-sheets in PrPSc (Caughey, Dong et 
al. 1991, Pan, Baldwin et al. 1993). In inherited prion diseases, mutations occurring 
in the PRNP gene alter protein folding and stability and promote the conversion to 
PrPSc. In infective cases, the endogenous PrPC becomes a substrate that is directly 
converted to PrPSc by a preformed PrPSc–aggregate. In sporadic cases, it is likely that 
PrPC folding is perturbed by environmental conditions favouring pathological 
conversion (Prusiner 1991, Prusiner 1994, Caughey 2003). 
 
STRAINS 
Prions exist as strains able to exhibit distinct prion disease phenotypes. Strains of 
prions have been defined by the pattern of protein aggregate deposition, 
histopathological lesion profiles, rapidity of disease progression and specific 
neuronal targets (Dickinson, Meikle et al. 1968). Mounting evidence suggests that 
the tropism of a prion strain is dictated by its tertiary or quaternary structure, which 
influences its ability to bind and interact with specific molecules (Mahal, Baker et al. 
2007, Aguzzi 2008). Indeed, the information for the specific conformation of a PrPSc 
protein resides in its supramolecular structure, as demonstrated in studies involving 
the transmission of FFI and familial Creutzfeldt-Jakob disease (fCJD) to transgenic 
mice (Telling, Parchi et al. 1996, Scott, Groth et al. 1997, Safar, Wille et al. 1998). 
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These observations suggest that PrPSc itself is the molecule in which the information 
of a specific prion strain is encrypted. 
 
PRION NEUROTOXICITY 
The mechanisms underlying neurodegeneration in prion diseases remain unknown. 
The contribution of apoptosis and oxidative stress in TSEs pathology has been 
described (Milhavet and Lehmann 2002), but little is known about the primary 
causes that lead to neurodegeneration. PrPSc was generally assumed to be the 
neurotoxic specie, acting through a gain-of-toxic-function mechanism. However, 
PrPSc itself is not sufficient to trigger disease progression, as the presence of the 
cellular prion protein is also required (Bueler, Aguzzi et al. 1993, Brandner, Raeber 
et al. 1996). Removal of PrPC from cell membrane has been shown to inhibit 
neurotoxicity (Chesebro, Trifilo et al. 2005). Ablation of PrPC in vivo reversed prion 
pathology in prion infected mice (Mallucci, Dickinson et al. 2003). Recently, it has 
been suggested that replication events are dissociated from prion-induced 
neurotoxicity (Hill and Collinge 2003, Halliday, Radford et al. 2014). The ability of 
PrPC to protect neurons from toxicity during prion infection is reduced as a 
consequence of its conversion to PrPSc (Roucou and LeBlanc 2005). Therefore, it is 
still under debate whether prion toxicity is due to a gain-of-function of oligomeric 
species, to a loss-of-function of PrPC or, most likely, to a combination of the two.  
 
CELLULAR PRION PROTEIN 
PrPC is encoded by a chromosomal gene denoted PRNP. PRNP gene belongs to the 
PRN gene family that includes also Doppel (Moore, Lee et al. 1999) and Shadoo 
proteins (Watts, Drisaldi et al. 2007). The gene itself is composed by two (in 
hamster and humans) or three exons (in rat, mouse, bovine, sheep), while the open 
reading frame of PrPC is encoded within a single exon (Basler, Oesch et al. 1986, 
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Westaway, Goodman et al. 1987). The other exons contain untranslated sequences 
including the promoter and the termination sites, to which the control of the PRNP 
gene expression has been attributed. The PrPC promoter contains GC-rich repeats, 
canonical binding site for the transcription factor Sp1, driving expression in many 
different tissues (Puckett, Concannon et al. 1991, Baybutt and Manson 1997). TATA 
box is absent from the gene. For these reasons PRNP is often labelled as a 
housekeeping gene. Alignment of PrPC translated sequences reveals a striking 
degree of conservation not only among mammals, but also in birds, reptiles, 
amphibians, ﬁsh and more primitive organisms such as insects and protozoa 
(Gabriel, Oesch et al. 1992, Simonic, Duga et al. 2000, Favre-Krey, Theodoridou et 
al. 2007). This evidence suggests the retention of some important function for PrPC 
through evolution. 
PrPC is an N-glycosylated, glycosylphosphatidylinositol (GPI)-anchored protein of 
208–209 aa. (Stahl, Borchelt et al. 1987). Mature PrPC is exported to the cell surface 
after cleavage of a 22-amino acid (aa) signal peptide and post-translational 
processing that occurs in the ER and Golgi. PrPC structure is characterized by a 
flexible random-coiled N-terminal domain and a C-terminal globular domain (Figure 
4). The unfolded N-terminal region consists of residues 23–124 and contains a 
stretch of several octapeptide repeats (OR) and two positively charged clusters, CC1 
(aa 23–27) and CC2 (aa 95–110), linked by a hydrophobic stretch known as the 
hydrophobic domain (HD, aa 111–129). The globular domain of human PrPC is 
arranged in three α-helices (aa 144–154, 173–194 and 200–228), interspersed with 
antiparallel β-sheets (aa 128–131 and 161–164). A single disulﬁde bond is found 
between cysteine residues 179 and 214 (Riek, Hornemann et al. 1996, Riek, 
Hornemann et al. 1997). Despite low sequence similarity between chicken, turtle 
and frog PrPC, and the highly conserved homology between mammalian, PrPC 
structural features are remarkably preserved (Calzolai, Lysek et al. 2005). Full-length 
PrPC is glycosylated in the Golgi apparatus in residues Asn-181 and Asn-197 in 
human and Asn-180 and Asn-196 in mice (Haraguchi, Fisher et al. 1989) (Figure 5). 
The variable occupancy of residues results in non-, mono-, di-glycosylated PrPC 
forms. The glycosylation pattern gives rise to a large variety of N-glycans attached 
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to both the full-length and truncated PrPC (Rudd, Endo et al. 1999, Pan, Wong et al. 
2002) and results in a different distribution of PrPC in the brain (DeArmond, Qiu et 
al. 1999, Beringue, Mallinson et al. 2003). The pattern of glycosylation seems to be 
involved in the susceptibility to conversion and to the diversity of TSEs (Lawson, 
Collins et al. 2005). 
 
Figure 4. Outline of the primary structure of the cellular prion protein including post-translational 
modifications. (Aguzzi and Calella 2009) 
 
 
Figure 5. Mature form of PrP
C
. PrP
C
 is a GPI-anchored membrane protein, with a flexible, random 
coil N-terminus and a globular C-terminal domain. The N-terminal domain of PrP
C
 contains the 
stretch of octapeptide repeats (in light blue), which binds divalent cations such as copper ions, the 
two positively charged clusters, CC1 (aa 23–27) and CC2 (aa 95–110) and the hydrophobic domain 
(HD). The C-terminal domain of PrP
C
 contains three alpha-helices (in pink) and two antiparallel β- 
sheets (in yellow). PrPC can be found in non-, mono-, or di-glycosylated forms (Caughey and Baron 
2006) 
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PrPC EXPRESSION AND LOCALIZATION 
Increase of PRNP expression is correlated with brain development, from the initial 
postnatal weeks till the end of the synaptogenesis, reaching a plateau during 
adulthood. Moreover, distribution and expression level of PrPC vary among distinct 
brain regions, cell types and neurochemical phenotypes, indicating a correlation 
between expression and neuronal differentiation (Manson, West et al. 1992, Sales, 
Hassig et al. 2002, Linden, Martins et al. 2008, Benvegnu, Poggiolini et al. 2010). In 
the central nervous system, PrPC expression has also been described in glial cells 
(Radovanovic, Braun et al. 2005, Bribian, Fontana et al. 2012). Moreover, PrPC is 
present in non-neuronal tissues, such as blood lymphocytes, gastro-epithelial cells, 
heart, kidney and muscles (Horiuchi, Yamazaki et al. 1995, Fournier, Escaig-Haye et 
al. 1998). 
 
PrPC KNOCK-OUT MICE 
Several non-co-isogenic lines of mice lacking PrPC have been generated by 
homologous recombination in embryonic stem cells, in order to shed light into PrPC 
physiological function. Disruptive modiﬁcations restricted to the open reading 
frame results in the known Prnpo/o [Zürich I] (Bueler, Fischer et al. 1992) or Prnp−/− 
[Edinburgh] (Manson, Clarke et al. 1994) lines. These mice developed normally, 
without severe pathologies. As predicted by the protein-only hypothesis, these mice 
were entirely resistant to prion infections (Bueler, Aguzzi et al. 1993). In contrast, 
three lines generated afterwards, Prnp−/− [Nagasaki], Rcm0, and Prnp−/− [Zürich II], 
developed ataxia and Purkinje cell loss later in life (Sakaguchi, Katamine et al. 1996, 
Moore, Lee et al. 1999, Rossi, Cozzio et al. 2001). The discrepancy with the previous 
lines was clarified with the discovery of Prnd, a gene located 16 kb downstream to 
Prnp encoding for a protein called Doppel (Dpl). In Prnp−/− [Nagasaki], Rcm0, and 
Prnp−/− [Zürich II] a splice acceptor site to the third exon of Prnp was deleted, 
placing the Prnd gene under the transcriptional control of the Prnp promoter. This 
resulted in a chimeric Prnp-Prnd product and in the overexpression of Dpl in the 
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brain (Moore, Lee et al. 1999), responsible for the brain phenotype. The effect of 
Dpl overexpression in these mice was rescued by reintroduction of Prnp gene 
(Nishida, Tremblay et al. 1999, Didonna, Sussman et al. 2012). Moreover, all Prnp−/− 
lines were generated in ES cells derived from the 129 strain of the laboratory mouse 
and maintained in non-129 backgrounds, except for the Prnp−/− [Edinburgh]. 
Consequently, a systematic genetic confounders happens when Prnp−/− and Prnp+/+ 
lines are compared, leading to the misleading attribution of altered physiological 
evidence to the lack of the Prnp gene. For example, an hyperphagocytosis of 
apoptotic cells in primary macrophages from PrP-/- mice (de Almeida, Chiarini et al. 
2005) was proved to be the result of a flanking gene problem, rather than of 
absence of PrPC (Nuvolone, Kana et al. 2013). To finally avoid the above-mentioned 
problems, Aguzzi group has successfully created a new co-isogenic line of PrP-/- mice 
[Zürich III] on pure C57BL/6J background.  
 
CELLULAR PROCESSES INFLUENCED BY PrPC 
EXPRESSION  
Although several studies have been carried out to underpin possible functions of 
PrPC and many lines of transgenic mice carrying mutations and deletions of PrPC 
have been established, straightforward evidence is still lacking to understand the 
physiological role and the molecular pathways leading to neurodegeneration in 
prion diseases. The flexible and unstructured N-terminal domain of PrPC resembles 
the group of intrinsically disordered proteins (IDP) which partially or entirely lack a 
globular structure (Dyson and Wright 2005, Uversky and Dunker 2010). This group 
comprises proteins that have been shown to be involved in cell signalling, protein-
protein interactions and regulation of transcription and chromatin remodelling. 
Examples of IDP are α-synuclein, associated to PD, and p53 and BRCA1 oncogenes, 
associated to tumor development. PrPC shares with these proteins in particular the 
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characteristic of molecular recognition of several partners, a feature that allows 
disordered proteins to switch functions (Tompa, Szasz et al. 2005).  
PrPC has been demonstrated to be involved in a number of physiological cellular 
processes including regulation of neuronal signalling and synaptic function and 
neuroprotection (Table 3).  
 
Table 3. Cellular distribution and activities of PrP
C
 in cell types in which known or putative 
functions have been described (Caughey and Baron 2006). 
 
PrPC SIGNALLING IN NEURONAL CELLS 
Since PrPC is mainly localized on the outer leaflet of the cell membrane as a GPI-
anchored protein, it has been extensively studied its role as a cell receptor. Upon 
binding, PrPC triggers intracellular signals, via its binding to other plasma membrane 
molecules, including laminin receptor and neural cell adhesion molecules 
(Gauczynski, Peyrin et al. 2001, Schmitt-Ulms, Legname et al. 2001). Signalling 
pathways that were found activated in vitro suggest an involvement of PrPC in 
neuronal development, differentiation and neurite outgrowth (Zanata, Lopes et al. 
2002, Chen, Mange et al. 2003, Kanaani, Prusiner et al. 2005, Santuccione, Sytnyk et 
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al. 2005). PrPC has been shown to induce rapid phosphorylation of ERK1/2 (Grewal, 
York et al. 1999) and its activation through the Fyn kinase cascade (Mouillet-
Richard, Ermonval et al. 2000, Schneider, Mutel et al. 2003). As a GPI-anchor 
protein, PrPC can transfer and transduce signals from cells to cells (Liu, Li et al. 
2002). The activation of the cAMP/protein kinase A (PKA) observed in retinal 
explants from neonatal mice using a PrP binding peptide (Chiarini, Freitas et al. 
2002) and the interaction of PrPC with the stress inducible protein 1 (STI1) suggest a 
neuroprotective role for PrPC in cells, through the activation of the ERK1/2 and PI3K-
Akt-mTor pathways (Zanata, Lopes et al. 2002, Roffe, Beraldo et al. 2010). 
Moreover, interaction with Grb2 adaptor protein in the endosomal compartment 
further stresses PrPC involvement in neuronal survival (Spielhaupter and Schatzl 
2001). The interaction with STI1 efficiently inhibited Aβ oligomers binding to PrPC in 
vitro and in mouse primary hippocampal neurons, preventing synaptic loss and 
neuronal death (Ostapchenko, Beraldo et al. 2013). Following the interaction of Aβ 
oligomers, PrPSc and other β-sheets peptides, the neuroprotective function of PrPC 
is lost and cells undergo PrPC-dependent induction of apoptosis via caspase 3 
(Resenberger, Harmeier et al. 2011). Moreover, PrPSc interaction with PrPC induces a 
Jun N-terminal kinase dependent pro-apoptotic signalling at the expense of the pro-
survival ERK1/2 signalling (Rambold, Muller et al. 2008).  
 
PrPC ROLE IN SYNAPSES 
The presence of PrPC in pre- (Herms, Tings et al. 1999) and postsynaptic structures 
(Haeberle, Ribaut-Barassin et al. 2000) argues for an important role of this protein 
in the normal development of synapses and in maintenance of their functionality 
(Moya, Sales et al. 2000, Kanaani, Prusiner et al. 2005). Moreover, the finding that 
some PrPC glycoforms can be selectively transported along axons suggests a specific 
presynaptic function (Rodolfo, Hassig et al. 1999). Prion diseases are characterized 
by synaptic disorganization and loss, irrespective of the presence or absence of 
spongiform changes (Clinton, Forsyth et al. 1993), phenomenon accompanied by 
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PrPSc deposition in synaptic terminals (Kitamoto, Shin et al. 1992, Grigoriev, Escaig-
Haye et al. 1999) and reduced exosomes-associated synaptic vesicle proteins in TSEs 
patients (Ferrer, Rivera et al. 1999). The importance of PrPC in synapses has been 
corroborated by electrophysiological studies in CA1 hippocampal neurons from PrP-
/- mic. In these neurons, excitatory glutamatergic synaptic transmission, GABAA 
receptor–mediated fast inhibition, long-term potentiation, and late after 
hyperpolarization were reduced or absent (Carleton, Tremblay et al. 2001, Mallucci, 
Ratte et al. 2002) when PrPC was missing. Moreover, synaptic dysfunction related to 
PrP-/- mice could be related to altered circadian rhythms and sleep (Tobler, Gaus et 
al. 1996) and impaired hippocampal dependent spatial learning (Criado, Sanchez-
Alavez et al. 2005).  
 
PROTECTION AGAINST OXIDATIVE STRESS 
Increasing evidence suggests that PrPC improves resistance to oxidative stress, 
through chelation of free copper ions responsible for reactive oxygen species (ROS) 
generation (Brown 2001). PrPC deficient neurons are more susceptible to oxidative 
stress than wild-type cells, an evidence explained in vivo by a reduction of the Cu/Zn 
superoxide dismutase (SOD) activity and high levels of oxidative damage to proteins 
and lipids (Brown, Schulz-Schaeffer et al. 1997, Brown, Nicholas et al. 2002). 
Injection of copper in the rat hippocampus results in memory impairment, neuronal 
loss and astrogliosis. This effect was rescued by co-injection of a peptide (PrP59-91) 
corresponding to the OR of PrPC, thus suggesting a regulatory role of PrPC in copper 
homeostasis (Chacon, Barria et al. 2003). Moreover, mitochondria morphological 
alterations have been described in scrapie infected hamsters (Choi, Ju et al. 1998) 
and mice (Lee, Sohn et al. 1999), as well as in mice lacking PrPC (Miele, Jeffrey et al. 
2002). Since mitochondria are important players in oxidative stress as well as in 
induction of apoptosis, it seems that the two effects are not mutually exclusive. 
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ANTIAPOPTOTIC FUNCTION  
A survival-promoting effect mediated by PrPC has been observed both in vitro and in 
vivo on neuronal and nonneuronal cells. Roucou and co-workers suggested a 
cytoprotective role of PrPC against Bax-mediated apoptosis in human primary 
neurons (Roucou, Guo et al. 2003, Roucou, Giannopoulos et al. 2005). This anti-
apoptotic function against Bax-mediated cell death was attributed to the similarity 
of the Bcl-2 homology domain (BH2) of the Bcl-2 proteins and the OR. 
Neuroprotection was nullified if the OR region of PrPC is completely deleted 
(Bounhar, Zhang et al. 2001). Overexpression of Bax and PrPC completely abolished 
Bax-mediated cell death, as well as did the co-expression of Bcl-2. The anti-Bax 
function requires a mature PrPC, as treatment of cells with inhibitors of transport 
through ER and Golgi as well and beyond trans-Golgi vesicles prevents PrPC anti-
apoptotic function. However, the GPI anchor is not essential for the anti-Bax 
function (Roucou, Giannopoulos et al. 2005). Furthermore, expression of PrPC in the 
cytosol is sufficient to inhibit Bax-mediated cell death (Roucou, Guo et al. 2003). 
These results are in line with previous findings on PrPC rescue from Bax-mediated 
apoptosis caused by serum deprivation in neuronal cells (Deckwerth, Elliott et al. 
1996, Kuwahara, Takeuchi et al. 1999). Protection from apoptosis was also 
investigated in a screening of gene-expression profile in a cell clone of MCF-7 breast 
cancer cells resistant to TNFα-induced apoptosis, where PrPC was found 
overexpressed. Conversely, MCF-7 cells acquired resistance to TNFα-induced 
apoptosis after overexpression of PrPC (Diarra-Mehrpour, Arrabal et al. 2004). 
However, PrPC does not protect human neuroblastoma SK-H-SH and BE(2)-M17 cell 
lines, mouse neuroblastoma N2a cells and human embryonic kidney 293 cells 
against Bax overexpression (Roucou, Gains et al. 2004). Neuroprotection of PrPC 
was confirmed in vivo in post-ischemic brain rodents which show a higher PrPC level 
compared to controls (Weise, Crome et al. 2004, Shyu, Lin et al. 2005) and in rat 
brains in which the overexpression of PrPC improved neurological behaviour after 
ischemia (Shyu, Lin et al. 2005). Moreover, in a model of focal brain ischemia, PrP-/- 
mice displayed three times larger infarct size compared to PrP+/+ mice (Mitteregger, 
Vosko et al. 2007). Mice deleting of aa 32-93 had infarct size similar to PrP-/- mice, 
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identifying the N-terminal domain as player in PrPC neuroprotection. Increased 
levels of caspase-3 and reduction of Akt activation were found in the ischemic 
brains (Spudich, Frigg et al. 2005, Weise, Sandau et al. 2006). 
 
CONTROVERSY AROUND PrPC ANTIAPOPTOTIC FUNCTION 
Depending on the cell type, overexpression of PrPC could results in a toxic effect 
rather than in protection. Human embryonic kidney 293 (HEK293), rabbit epithelial 
Rov9, murine cortical TSM1 cell lines are susceptible to the apoptotic inducer 
staurosporine when PrPC is overexpressed (Paitel, Fahraeus et al. 2003). Apoptosis 
in these cells is mediated through p53 (Paitel, Sunyach et al. 2004). These results, 
that are in contrast with the Bax-mediated anti-apoptotic function of PrPC, could be 
explained by several causes. PrPC overproduction may interfere with the production 
of essential proteins in these cells. PrPC overexpression may lead to the formation 
of the transmembrane form of PrP, CtmPrP, characterized by the N-terminal in the 
cytoplasm and the C-terminal facing the ER lumen. CtmPrP induces neuronal cell 
death in vitro and in vivo (Hegde, Mastrianni et al. 1998). Cytosolic PrPC, retro-
translocated from the ER, could be toxic in N2a cell line and cerebellar granule 
neurons in mice (Ma and Lindquist 2001, Yedidia, Horonchik et al. 2001, Ma, 
Wollmann et al. 2002) or non- toxic in HEK293, COS-1, BE(2)-M17 and SK-N-SH cells 
and human primary neurons (Drisaldi, Stewart et al. 2003, Heller, Winklhofer et al. 
2003). In light of this, it can be postulated that the effect of PrPC depends on the cell 
type. Alternatively, when overexpressed, PrPC could be converted in a lethal 
protein. As Bcl-2 and Bcl-xL cleavage by endogenous caspases results in a 
proapoptotic carboxy-terminal fragment (Cheng, Kirsch et al. 1997, Clem, Cheng et 
al. 1998), PrPC cleavage in the caspase-like site at aa145 could generate a toxic 
fragment. Indeed, the PrP 145STOP mutation is associated to a vascular form of prion 
disease (Kitamoto, Iizuka et al. 1993, Ghetti, Piccardo et al. 1996). 
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NEUROPROTECTION AGAINST Dpl AND N-TERMINALLY 
TRUNCATED PrPC MEDIATED CELL DEATH  
As mentioned above, re-expression of PrPC in mice depleted from Prnp and 
overexpressing Dpl, rescues cerebellar Purkinje cells loss and ataxia (Nishida, 
Tremblay et al. 1999). Two mechanisms could explain the neuroprotective function 
of PrPC. PrPC and Dpl could compete for the same ligand, and the overexpression of 
Dpl prevents survival mechanisms activated by the binding of PrPC (Behrens and 
Aguzzi 2002). Alternatively, Dpl could cause oxidative stress, an effect counteracted 
by the presence of the anti-oxidant property of PrPC (Wong, Liu et al. 2001). Mice 
expressing a truncated NH2-terminal PrPC (PrP Δ32-134) died of severe ataxia 1-3 
months after birth. Re-expression of a single PrPC allele was sufficient for rescue the 
disease. The PrPC deleted domain is absent in Dpl, thus suggesting a common 
mechanism in the induction of the disease. In absence of PrPC, PrPΔ32-134 could 
still bind to a putative ligand, but would not results in a survival signals (Shmerling, 
Hegyi et al. 1998). 
 
HD DOMAIN AS THE PrPC NEUROPROTECTIVE FRAGMENT 
The HD domain has acquired increasing interest because of its role in different 
modulations of PrPC. Besides membrane integration of minor topological isoforms, 
it has been found to be involved in α-cleavage and dimerization. Human PrPC is 
physiologically β- and α-cleaved at amino acids 89/90 and 110–111/112, while a 
cleavage at amino acids 228/229 results in ectodomain shedding (Chen, Teplow et 
al. 1995, Mange, Beranger et al. 2004, Taylor, Parkin et al. 2009). α-cleavage 
produces a 17 kDa, N-terminally truncated fragment (PrPC1), anchored to the 
plasma membrane and a secreted 11kDa fragment (PrPN1) (Chen, Teplow et al. 
1995, Mange, Beranger et al. 2004) (Figure 6). Mice overexpressing PrPC1 do not 
show a neurotoxic phenotype (Westergard, Turnbaugh et al. 2011) and PrPC1 is 
associated with protection against infection with the prion strain M1000 in cultured 
cells (Lewis, Hill et al. 2009). Moreover, PrPC1 acts as a dominant-negative inhibitor 
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of PrPSc conversion in vivo (Meier, Genoud et al. 2003, Westergard, Turnbaugh et al. 
2011). Neuroprotection is also attributed to PrPN1 against in vivo ischemic stress 
and against oligomeric amyloid-β (Aβ)-associated cell death in primary neurons 
(Guillot-Sestier, Sunyach et al. 2009, Resenberger, Harmeier et al. 2011). The 
presence of amorphous aggregates of Aβ and PrPN1 and the increased levels of PrP 
α-cleavage in post mortem brain tissues from AD patients (Beland, Bedard et al. 
2014) strongly support a neuroprotective mechanism mediated by the α-cleavage. 
In favour of this neuroprotective hypothesis, PrPSc and toxic PrPC mutants are 
impaired in their α-cleavage (Oliveira-Martins, Yusa et al. 2010). Several studies 
demonstrate that the HD of PrPC is essential for α-cleavage (Bremer, Baumann et al. 
2010, Oliveira-Martins, Yusa et al. 2010). Interestingly, the HD is also essential for 
PrPC homodimerization on the cell surface, a process that regulates PrPC 
physiological neuroprotective/neurotrophic activities (Rambold, Muller et al. 2008). 
Stimulation of PrPC dimerization in cell culture increases both PrPC trafficking to the 
cell surface and the formation of all extracellular PrPC metabolites: PrPN1,  PrPC1 
and shed PrPC (Beland, Motard et al. 2012). Deletion of HD does not prevent PrPC 
trafﬁcking to the plasma membrane (Winklhofer, Heller et al. 2003), suggesting a 
non-essential role of dimerization for PrPC trafﬁcking. Roucou and colleagues 
proposed a model with a constitutive and dimerization-independent pathway for 
PrPC secretion and a pathway regulated by dimerization (Figure 6). With this model, 
the cells are allowed to quickly respond to toxic insults by increasing the levels of 
protective PrPC metabolites (Beland and Roucou 2013).  
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Figure 6. PrP
C
 dimerization activates a neuroprotective signalling pathway and the production of 
neuroprotective PrP
C
-derived metabolites (Roucou 2014). 
 
IMMUNE SYSTEM 
Expression of PrPC is differently regulated among the immune system, suggesting a 
specific role on the basis of the cellular type. However, the lack of PrPC does not 
affect the maturation of immune cell compartments (Isaacs, Jackson et al. 2006). 
PrPC sustains the self-renewal of hematopoietic stem cells (HSC) under stress 
conditions (Zhang, Steele et al. 2006) and is highly expressed in lymphocytes 
(Cashman, Loertscher et al. 1990). This evidence confers a putative role to PrPC in 
mediating immune responses. PrPC co-localizes with the T-cell receptor (TCR) in lipid 
rafts (Stuermer, Langhorst et al. 2004) and cooperates with TCR in T cell activation 
(Thomas, DeGasperi et al. 1991, Mattei, Garofalo et al. 2004). Within the T-cell 
compartment, CD8+ cells are characterized by a higher PrPC expression level than 
CD4+ cells. CD3+ cells co-expressing the activation marker CD56 (N-CAM) exhibited 
signiﬁcantly higher levels of PrPC if compared to CD56 counterparts (Durig, Giese et 
al. 2000). In dendritic cells (DCs) PrPC has been found to increase during maturation, 
when it co-localize with MHC class II (Burthem, Urban et al. 2001, Martinez del 
Hoyo, Lopez-Bravo et al. 2006) However, PrPC expression it is not required for full 
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maturation of DCs. The importance of PrPC in the regulation of the immunological 
synapse between DC and T-cell was strongly evidenced (Ballerini, Gourdain et al. 
2006). Several studies have highlighted that prion infection occurs and propagate 
within in the immune system (McBride, Eikelenboom et al. 1992, Jeffrey, McGovern 
et al. 2000, Klein and Aguzzi 2000, Beringue, Couvreur et al. 2002, Prinz, Montrasio 
et al. 2002). While circulating lymphocytes do not show any detectable infectivity, B 
cells in lymphoid organs are able to accumulate prions in a PrPC-dependent fashion, 
(Raeber, Klein et al. 1999). Susceptibility to peripheral prions in lymph nodes was 
observed even in the absence of follicular dendritic cells. Therefore, it is possible 
that poorly defined immune cells or stromal precursor cells might be capable of 
replicating prions (Kaeser, Klein et al. 2001, Prinz, Montrasio et al. 2002). 
 
PrPC TRAFFICKING 
ENDOPLASMIC RETICULUM (ER) TRANSLOCATION 
During translation, PrPC is translocated to the ER following the recognition of an N-
terminal signal peptide, that is cleaved in the ER lumen. The signal sequence is 
characterized by a “weak” efficiency of translocation if compared to other proteins 
and results in the segregation of different PrPC populations. The NtmPrP, the C-
terminus of which faces the cytosol, and the secreted PrP (secPrP) are characterized 
by the N-terminus in the ER lumen. On the contrary, the CtmPrP, with the N-terminus 
facing the cytosol, and the cytosolic PrP(cyPrP) have the N-terminus in the 
cytoplasm (Figure 7). PrPC ER translocation is regulated by the HD domain, which 
acts as an internal signal sequence that competes with the N-terminal signal of PrPC 
(Hegde and Lingappa 1999). Nascent chains, that fail to rapidly target the translocon 
after synthesis of the N-terminal signal, could target via the HD. The result is the 
generation of CtmPrP (Kim, Rahbar et al. 2001, Kim and Hegde 2002). Indeed, in vitro 
synthesized CtmPrP contains an uncleaved signal sequence (Stewart, Drisaldi et al. 
2001). This feature is beneficial during ER stress since it reduces the translocation 
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into the ER, thus preventing PrP aggregation in the secretory pathway (Kang, Rane 
et al. 2006). However, it is detrimental in the context of genetic mutation in prion 
diseases. Indeed, natural point mutants in human PrPC that present CtmPrP are 
associated with GSS, in the case of PrP(A117V) and PrP(G131V) (Tateishi, Kitamoto 
et al. 1990, Hsiao, Cass et al. 1991, Panegyres, Toufexis et al. 2001), as well as with 
CJD, as for PrP(G114V) (Liu, Jia et al. 2010). The common feature of all these mutant 
forms of PrPC is an increased HD hydrophobicity, which influence the efficiency and 
timing of the post targeting function of the signal sequence in initiating N-terminus 
translocation (Kim and Hegde 2002). Substitution of the signal sequence of PrPC 
with the more efficient prolactin one in mice, revert the effect of GSS mutants 
improving the formation of secPrP and rescuing animals from the disease (Rane, 
Chakrabarti et al. 2010). 
 
Figure 7. Signal efficiency mediated formation of different PrP
C 
populations. (A) Line diagram 
showing elements involved in PrP
C
 translocation. (B) Steps in PrP
C
 translocation. PrP
C
 is targeted to a 
Sec61 translocon via its N-terminal signal sequence. Translocation initiates when Sec61 interacts 
with gates and open the channel. Further protein synthesis results in complete translocation into the 
ER lumen to generate 
sec
PrP. This pathway is followed by the majority of PrP
C
 polypeptides 
synthesized. Bottom: intrinsic inefficiencies in the signal sequence interaction with the translocon 
can cause a small proportion of PrP
C
 polypeptides to fail at the crucial gating/initiation steps. In the 
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first case, the polypeptide is expelled into the cytosol to generate cyPrP. Alternatively, the central 
HD, particularly if carrying a mutation that increases hydrophobicity, can engage the nearby 
translocon to generate 
Ctm
PrP (Rane, Chakrabarti et al. 2010). 
 
MATURATION IN THE SECRETORY PATHWAY 
During passage in the ER, PrPC undergoes N-glycosylation of null, one or two glycans 
to the two asparagine residue in position 181 and 197, in human. Several 
modifications are made on the N-linked glycan chains and a disulphide bond is 
formed between its two cysteines (C180 and C214). Once added of the GPI anchor, 
PrPC is translocated to the Golgi apparatus, where the association with distinct 
membrane rafts is necessary for the correct fording of the protein (Sarnataro, 
Campana et al. 2004). Finally, the protein is exocytosed to the cellular membrane 
where is usually localized in lipid rafts domains (Lewis and Hooper 2011). 
 
ENDOCYTOSIS 
PrPC could re-enter the cell with different ways of endocytosis: the most common 
lipid rafts, or caveolae-like domains, that drive also the internalization of PrPSc (Vey, 
Pilkuhn et al. 1996) and the clathrin-coated vesicles (Peters, Mironov et al. 2003). 
Alternatively, endocytosis of PrPC has been observed upon interaction with laminin 
receptor (Gauczynski, Peyrin et al. 2001). It is likely that small GTP binding Rab 
proteins could control PrPC trafficking (Zerial and McBride 2001). Rab7 was found to 
co-localize with PrPSc in late endosomes and lysosomes (Magalhaes, Baron et al. 
2005), while Rab6 is involved in the retrograde transport of the PrPSc and may also 
regulate trafficking of PrPC (Beranger, Mange et al. 2002). Only a small fraction of 
the endocytosed PrPC is degraded by the lysosomes, while a large fraction returns 
to the cell surface. Moreover, in the intracellular trafficking of PrPSc, part of the 
recycled PrPC is secreted to the extracellular space with exosomes (Fevrier, Vilette 
et al. 2004, Porto-Carreiro, Fevrier et al. 2005, Robertson, Booth et al. 2006).  
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Endocytosis should not be only investigated as a way for the internalization and 
propagation of PrPSc (Laszlo, Lowe et al. 1992), but also for putative PrPC 
physiological roles. PrPC could be seen as a broad-spectrum sensor at the cell 
surface. PrPC ligand-mediated internalization could serve as transport and 
homeostasis of different ligands, including copper and hemin (Vassallo and Herms 
2003, Lee, Raymond et al. 2007). It may regulate intracellular signalling after 
extracellular stimulation (Prado, Alves-Silva et al. 2004, Americo, Chiarini et al. 
2007, Caetano, Lopes et al. 2008)or control PrPC degradation (Kiachopoulos, Heske 
et al. 2004). 
  
Figure 8: Endocytosis and subcellular localization of PrP
C
 (Prado, Alves-Silva et al. 2004). 
 
CYTOSOLIC PrP 
A variable amount of PrPC has been found in the cytoplasm after Prnp 
overexpression but also in a subset of cerebellar neurons (Mironov, Latawiec et al. 
2003).In physiological conditions, when ER quality control and UPS systems are fully 
functional, PrPC is rarely detected in the cytoplasm. Instead, under ER-stress 
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conditions, translocation of nascent PrPC into the ER is prevented, thus resulting in 
increased levels of PrPC in the cytosol (Kang, Rane et al. 2006, Orsi, Fioriti et al. 
2006). Moreover, when the activity of the proteasome system is compromised, PrPC 
rapidly accumulates in the cytoplasm, suggesting the existence of a constant flux of 
unfolded or misfolded PrPC to this compartment. In this view, PrPC would appear in 
the cytoplasm when aging or environmental stresses compromise the system (Ma 
and Lindquist 2001). In prion pathology, two mutations related to the GSS, the 
Q217R and Y145STOP, generate mutated forms of PrP
C that accumulate in the ER and 
other membrane-bound compartments when proteasome activity is blocked 
(Zanusso, Petersen et al. 1999). Interestingly, prion-infected mice have cytoplasmic 
PrPC aggregates (Kristiansen, Messenger et al. 2005). However, it is still under 
debate if the presence of PrPC in the cytosol is directly associated to neuronal 
pathogenesis (Ma and Lindquist 2001, Ma, Wollmann et al. 2002, Wang, Wang et al. 
2005, Campana, Sarnataro et al. 2006, Orsi, Fioriti et al. 2006, Wang, Wang et al. 
2006) or it exerts a physiological/ neuroprotective function (Roucou, Guo et al. 
2003, Fioriti, Dossena et al. 2005, Jodoin, Laroche-Pierre et al. 2007), as discussed 
before.  
 
MECHANISMS OF ACCUMULATION AND 
DEGRADATION 
The fate of PrPC inside the cells is still subjected to intense study. Presently, the 
mechanisms leading to the formation of PrPC aggregates are unknown. Most 
importantly, it still needs to be clarified the role of aggregates both in the 
physiological settings and in the pathological conditions. First of all, it has to be 
clarify that protein aggregation is a continuous process in cells. Many physiological 
processes depend on the transient aggregation of proteins. In other cases, protein 
aggregates result from misfolding caused by stress conditions. Damaged proteins 
are degraded by the proteasome or by chaperone-mediated autophagy when 
processed by single peptides units. Undissolved large protein aggregates are 
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degraded by macroautophagy (aggrephagy). The degradation system becomes 
compromised in conditions of overwhelm of misformed proteins or toxic 
pathological forms. However, it is still not clear if the formation of aggregates is a 
cytoprotective mechanism, aimed at sequestering toxic proteins to avoid cellular 
damage.  
 
PATHOLOGICAL AGGREGATES 
In neurodegenerative diseases, classical protein aggregation follows the model of 
mass action and energy minimization proposed by Dobson and Lansbury (Jarrett 
and Lansbury 1993, Dobson 2003): aggregation prone proteins are present in the 
cell as monomers, that misfold randomly in a process devoid of biological function. 
In this model, the formation of aggregates is dependent on the amount of starting 
material and by the HD, which determines the propensity of the protein to 
aggregate. Oligomers and fibrils that derive from this process overcome the action 
of chaperones and of the proteasomal and autophagic systems, resulting in cell 
death and inflammation (Figure 9). Broader neurodegeneration is explained in this 
way as the amyloid cascade (Selkoe and Schenk 2003). This model well suits for 
example the cases of PD and prion diseases, where aggregates of misfolded α-
synuclein or PrPSc are found in neuronal cells throughout the CNS.  
 
 
Figure 9: conventional model for degenerative disease based on mass action and hydrophobic 
interactions. Monomeric proteins randomly misfold. The chaperone system, including heat shock 
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proteins (HSPs), can reverse the misfolding, and produce normal, functional proteins. However, the 
misfolded proteins are prone to random oligomerization. The oligomers aggregate further to form 
fibrillar aggregates. Formation of oligomers and fibrils is considered to lack normal protein biological 
functions. These oligomers and fibrillar aggregates can be removed by degradation, which occurs 
through the actions of the autophagic system and the ubiquitin proteasomal system. (Wolozin 2012) 
 
OTHER CELLULAR AGGREGATES 
The classical model of pathological aggregation contrasts with the highly regulated 
and reversible aggregation that occurs in the biology of RNA binding proteins. Many 
of these proteins have been found to be involved in motor neuron diseases. These 
proteins contain a hydrophobic glycine motif, that mediates their reversible 
aggregation, and a RNA recognition motif (RRM)(Kim, Kuwano et al. 2007). 
Aggregation of RNA binding proteins with bound RNA form an insoluble 
macromolecular structure, named stress granule (SG). The function of SG is to shift 
quickly RNA translation towards cytoprotective proteins (Kedersha, Cho et al. 2000). 
SG formation is well understood in pathway of ER- stress conditions (Kedersha and 
Anderson 2007). The yeast Sup35 protein, a termination factor that assists in proper 
protein translation, aggregates in an analogous way. Moreover, Sup35 undergoes 
self-perpetuating changes in conformation and is epigenetically inherited upon cell 
division or by mating (Wickner 1994). In an elegant study conducted by the group of 
Vorberg, it was demonstrated that cyPrP and C-terminal PrPC (PrP 90-231) are able 
to aggregate in a Sup35-like fashion, as a spontaneous event in the cell, rather than 
depending on sequestration in aggregation-prone proteins (Krammer, Suhre et al. 
2008). Independently from its intrinsic ability to aggregate, cyPrP inhibits the 
formation of SGs by sequestering the RNA into aggresomes (Beaudoin, Goggin et al. 
2008) and block Hsp70 synthesis. Inhibition of the stress-response could be the 
explanation of the toxicity of cyPrP observed in vivo and the reason of a short cyPrP 
permanence in the cytosol (Roucou 2009). To conclude, this evidence suggests that 
aggregate formation is not necessarily dictated by misfolded proteins. 
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A second type of aggregates is represented by aggresomes. Aggresomes have a 
juxtanuclear localization, at the centrosome (or microtubule organizing centre , 
MTOC), are positive for γ-tubulin and are surrounded by a cage of vimentin 
filaments. Aggresome formation is regulated by the microtubule-associated histone 
deacetylase 6 (HDAC6). Upon binding to their Lys63-polyubiquitylated chains (Hook, 
Orian et al. 2002, Du, Wang et al. 2014), HDAC6 recruits misfolded proteins to 
dynein motors on microtubules (Johnston, Ward et al. 1998, Hubbert, Guardiola et 
al. 2002). Deposition of protein aggregates into aggresomes has been proposed as a 
common mechanism in neurodegenerative diseases (Johnston, Ward et al. 1998). 
The regulation of HDAC6 in the formation of cytoplasmic aggregates in PD, HD (Tran 
and Miller 1999) and its presence in Lewy bodies (McNaught, Shashidharan et al. 
2002) suggests a link between the formation of aggresomes and pathological 
aggregates. Lys63-linked polyubiquitylation promoted by the E3 ubiquitin ligase 
Parkin results in HDAC6-mediated transport into aggregates under condition of 
proteasomal impairment (Olzmann, Li et al. 2007, Tan, Wong et al. 2008). 
Moreover, it underlies HDAC6 function in reducing the effect of misfolded protein-
induced stress (Taylor, Tanaka et al. 2003). Indeed, formation of aggregates may 
have a cytoprotective function (Tanaka, Kim et al. 2004, Chesebro, Trifilo et al. 
2005, Cohen, Bieschke et al. 2006, Douglas, Treusch et al. 2008), and might also 
facilitate the efficiency of aggregate removal by autophagic clearance (Taylor, 
Tanaka et al. 2003, Kaganovich, Kopito et al. 2008, Tan, Wong et al. 2008), as seen 
in models of PD, HD and spinobulbar muscular atrophy (SBMA) (Webb, Ravikumar 
et al. 2003, Iwata, Riley et al. 2005, Pandey, Nie et al. 2007, Su, Shi et al. 2011). 
Cytotoxicity of PrP106-126 peptide is regulated by HDAC6 through the induction of 
autophagy and activation of the PI3K-Akt-mTOR axis (Zhu, Zhao et al. 2016). 
Mutants that are not fully translocated in the ER (PrP V203L, E211Q and Q212P) are 
found in aggresomes in M17 human neuroblastoma cells (Mishra, Bose et al. 2003). 
However, cyPrP (PrP 90-231) is found in aggresomes in N2a cells, but not in Hela, 
Cos-7 and Huh-7 cells, where it is present in dispersed aggregates, that do not share 
characteristic features of aggresomes (Beaudoin, Goggin et al. 2008). This evidence 
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suggests that aggresomes are not the only final product of protein misfolding, and 
that other mechanisms of protein sequestration have to be investigated.  
 
Figure 10. Model for HDAC6-dependent processing of misfolded proteins and aggresome 
formation. (Kawaguchi, Kovacs et al. 2003) 
 
Another way to sequester misfolded proteins is represented by the accumulation in 
sequestosome, by the action of SQSTM-1/p62. Polyubiquitylated proteins are 
sequestered and degraded by the autophagolysosomal pathway (Bjorkoy, Lamark et 
al. 2005, Komatsu, Waguri et al. 2007, Pankiv, Clausen et al. 2007, Ichimura, 
Kumanomidou et al. 2008) or linked to the proteasome (Seibenhener, Babu et al. 
2004). SQSTM-1 is present in neurofibrillary tangles in the early phase of AD 
(Kuusisto, Salminen et al. 2002). In vitro evidence for p62-mediated pathological 
PrPC degradation is found in the clearance of PrPSc (Homma, Ishibashi et al. 2014) as 
well as of cyPrP and PrP-PG14, a mutant with an extra nine-octapeptide insertion 
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associated to CJD in HEK293 cells (Xu, Zhang et al. 2014). Sequestosomes are 
thought to be the equivalent of aggresomes in neurodegenerative diseases (Shin 
1998, Zatloukal, Stumptner et al. 2002). 
Another kind of distinction has to be done in order to define two subcellular 
compartments: the juxtanuclear quality control (JUNQ) and the insoluble protein 
deposit (IPOD). JUNQ is distributed along the ER, where cellular quality control 
components could efficiently clear misfolded proteins that are retrotranslocated 
from the ER. Ubiquitin, chaperones and the 26S proteasome components are 
present in the proximity of JUNQ. On the contrary, IPOD are inert aggregates of 
insoluble not-ubiquitylated sequestered proteins (Kaganovich, Kopito et al. 2008). 
Involvement of IPOD in the disaggregation of the prion protein has also been 
postulated (Muchowski and Wacker 2005). 
 
CLEARANCE MECHANISMS 
The autophagic system and the ubiquitin/proteasome system (UPS) are the main 
proteolytic systems involved in the cellular protein quality control (Ciechanover 
2005). Molecular chaperones and cargo-recognition molecules are involved in 
defining the fate of degradation of cellular proteins (Douglas, Summers et al. 2009). 
 
THE AUTOPHAGIC SYSTEM 
In the autophagic system, the catalytic component is represented by the lysosome. 
The lysosomal lumen is reached by cytosolic proteins for degradation via three 
different mechanisms: macroautophagy, microautophagy and chaperone-mediated 
autophagy (CMA) (Lynch-Day, Mao et al. 2012). In macroautophagy, a whole region 
of the cytosol is sequestered into a double membrane vesicle that fuses with 
lysosomes. In microautophagy, invagination of the lysosomal membrane traps 
regions of the cytosol that are internalized into the lysosomal lumen as single 
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membrane vesicles. Lastly, in chaperone-mediated autophagy, a targeting motif in 
the substrate proteins is recognized by a cytosolic chaperone that delivers it to the 
surface of the lysosome. Binding of the substrate to a lysosomal receptor leads to 
its multimerization and to the formation of a translocation complex. A luminal 
chaperone mediates the translocation of the substrate protein into the lumen 
where it is rapidly degraded (Figure 11). 
 
Figure 11. Autophagic pathways. (Wong and Cuervo 2010) 
 
Hsc70, the heat shock-cognate protein of 70 kDa, is the constitutive chaperone 
involved in CMA. Once bound to Hsc70, the substrate is targeted to the lysosome 
where it interacts with the single-span membrane protein lysosome-associated 
membrane protein type 2 (LAMP2) (Cuervo and Dice 1996). Increased levels of α-
synuclein and LRRK2 beyond a tolerable threshold results in toxic effect on CMA 
(Cuervo, Stefanis et al. 2004, Orenstein, Kuo et al. 2013). In chronically-infected 
cells, autophagy appears to be the major route of delivery of PrPSc into lysosomes 
(Heiseke, Aguib et al. 2010, Yao, Zhao et al. 2013) Indeed, late endosomes, 
lysosomes and autophagic vesicles increase greatly in prion-infected brain tissue 
(Boellaard, Kao et al. 1991, Sikorska, Liberski et al. 2004, Liberski, Sikorska et al. 
2010). In Figure 12 the pathway of PrPSc cell entrance, replication and degradation is 
shown  
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Figure 12. PrP
Sc
 formation, trafficking and degradation. Schematic illustration of the PrP
Sc
 
metabolism. PrP
Sc
 forms at the plasma membrane or shortly after endocytosis in endosomes, 
endocytic recycling compartment (ERC) or lysosomes. Prion propagation is allowed by recycling of 
PrP
Sc
 to the plasma . Newly formed PrP
Sc
 undergoes retrograde transport to the trans Golgi network 
(TGN) and Golgi where it is subject to the Golgi quality control and trafficked to lysosomes for 
degradation. More mature forms of PrP
Sc
 are trafficked to lysosomes via the endolysosomal and 
autophagic pathways. PrP
Sc
 may reach the cytosol through lysosomal rupture or ERAD, and 
accumulates in aggresomes when the proteasomal activity is impaired. Proteasomal degradation 
follows aggregates unfolding and ubiquitylation Aggresomal PrP
Sc
 and smaller insoluble forms are 
engulfed by phagophores and degraded by autophagic pathways (Goold, McKinnon et al. 2015) 
 
THE UBIQUITIN-PROTEASOME SYSTEM 
The UPS regulates the degradation of extra-lysosomal cytosolic, nuclear and ER-
residing proteins. The tagging molecule involved in UPS-mediated degradation is 
ubiquitin. Once tagged to the substrate protein, ubiquitin leads to its degradation 
by the 26S proteasome. The 26S proteasome is found next to the intermediate 
filaments of the cytoskeleton (Scherrer and Bey 1994) and in association with the 
cytoplasmic side of the ER membrane (Palmer, Rivett et al. 1996, Reits, Benham et 
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al. 1997). A close relationship exists between UPS activity and ER stress: when the 
proteasome is inhibited, it induces ER stress and vice versa (Lee, Iwakoshi et al. 
2003, Menendez-Benito, Verhoef et al. 2005). Impairment or overload of the UPS 
are likely to be the major contributors to the aggregation of ubiquitylated proteins 
in neuronal inclusion bodies. Indeed, in protein conformational disorder, the 
proteasome is directly targeted by the pathogenic proteins. Huntingtin, tau and α-
synuclein inhibit proteasome activity by clogging the entrance of other substrates 
(Keck, Nitsch et al. 2003, Landles and Bates 2004, Bennett, Bence et al. 2005, 
Betarbet, Sherer et al. 2005). Oligomers of PrPSc are able to inhibit proteasome 
activity by blocking the β subunits of the 26S proteasome (Kristiansen, Messenger 
et al. 2005) (see the “UBIQUITYLATION OF PrPC” section for further in-depth analysis 
of the UPS involvement in PrPC degradation).  
It is likely that in neurodegenerative conditions, an interconnection between 
different quality control systems and the various nature of toxically aggregated or 
misfolded proteins, as well as mutations in quality control players, results in the 
impairment of cell clearance and in the formation of aggregates. As previously 
described, this could be a way that the cells utilize to overcome the degenerative 
process.  
 
THE UBIQUITIN CODE 
Ubiquitin (Ub) is a highly stable molecule of 8 kDa, evolutionarily conserved from 
yeast to men. The essential role of ubiquitin is to generate a code, which triggers 
specific outcomes in the cell. According to linkage and fate, ubiquitin is covalently 
attached to lysine (Lys) residues of a target protein (ubiquitylation). Ubiquitylation 
is the result of the subsequent action of three different enzymes. The E1 Ub-
activating enzyme forms a thioester bond between its catalytic cysteine and a Ub 
molecule in an ATP-dependent manner. Ub is then transferred to the catalytic 
cysteine of an E2 Ub-conjugating enzyme. An E3 ligating enzyme (ubiquitin ligase) is 
responsible for the transfer and covalent binding of the Ub from the E2 to the 
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substrate protein. Two different type of E3 proteins exists. The RING E3 ubiquitin 
ligase, that binds to both the Ub-charged E2 and the protein substrate to mediate 
transfer of the Ub C-terminus to a substrate lysine to form an isopeptide bond, 
resulting in protein ubiquitylation. Conversely, HECT E3 ligases accept first the Ub 
onto a catalytic cysteine and then transfer the C-terminus of Ub to a substrate 
lysine via a isopeptide bond. (Pickart and Eddins 2004). The ubiquitin pathway is 
characterize by a high versatility. First, ubiquitylation mode is affected by the  
combination of different E2 and E3 proteins, that catalyse the formation of distinct 
protein-Ub structures (Deshaies and Joazeiro 2009, Ye and Rape 2009). Second, Ub 
binding proteins possess different Ub binding domains (UBDs) that selectively 
recognize structural characteristics on a Ub molecule near its lysine (Lys) residues 
(Komander 2009, Ikeda, Crosetto et al. 2010). Third, the kind of Ub linkage formed 
can result in a compact conformation if Lys 48, Lys6 and Lys11 residues are 
involved, or in an open conformation when Met1 or Lys63 residues are involved. 
The resulting conformational flexibility/rigidity raises the possibility that UBDs 
remodel chains to increase interaction interfaces or to improve specificity (Sims and 
Cohen 2009, Bremm, Freund et al. 2010, Matsumoto, Wickliffe et al. 2010, Virdee, 
Ye et al. 2010).  
 
CLASSIFICATION OF CLASSICAL AND ATYPICAL UB CHAINS 
The classical known polyubiquitin chain is formed via Lys48 and discovered as a 
destruction tag for proteasomal degradation. However, several kinds of Ub chains 
exists (Figure 13). Homotypic chains are formed by the conjugation of a single type 
of Lys residue in sequential Ub molecules, whereas mixed-linkage chains are 
assembled through distinct Lys residues on Ub molecules. Moreover, a bifurcations 
could arise in mixed-linked chains, resulting in Lys6/11, Lys29/48 or Lys29/33 linked 
chains (Kim, Kim et al. 2007). Further modifications are applied by Ub-like modifiers 
such as SUMO and NEDD8, resulting in heterologous chains. Also, many mono Ubs 
attached to the substrate in a spatially packed proximity can be considered as 
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atypical Ub signals. Atypical ubiquitylation is involved in different non proteolytic 
signals, regulating signaling pathways, trafficking and localization of substrate 
proteins, as well as substrate’s activity. 
 
Figure 13. Schematic model of possible ubiquitin chain formations on a target protein. A) 
Homotypic atypical chains. B) Mixed-linkage atypical chains in which the use of different Lys for 
sequential Ub conjugation leads to the formation of bifurcated chains. C) Heterologous chains are 
formed between Ub and ubiquitin-like proteins, for example the small ubiquitin-like modifier 2 
(SUMO2). D) multivalent chain-like Ub signals: multiple monoubiquitylation. (Ikeda and Dikic 2008). 
 
PHYSIOLOGICAL ROLE OF ATYPICAL CHAINS 
Regulation of protein activity is well explained for the NF-κB signaling, which 
involves different kind of Ub chains. NF-κB activation by TNF-α evokes different 
responses in the cells, include innate immune responses, cell survival, cell death and 
inflammation (Locksley, Killeen et al. 2001). Lys48 and Lys27 chains are necessary 
for the assembly of protein complexes, Lys48 chain for the degradation of the NF-κB 
inhibitor, E3 TRAF6 mediated Lys63 chain, cIAP1 mediated mixed Lys63/11 chain 
and LUBAC mediated Met1 chain are used for activation of IKK and its binding to the 
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TAK1 kinase complex (Deng, Wang et al. 2000, Wang, Deng et al. 2001, Dynek, 
Goncharov et al. 2010). Changes in localization of p53 protein is deciphered by 
multimonoubiquitylation (Li, Brooks et al. 2003). Regulation in protein interactions 
are likely to happen via Lys63 chains, as observed in the stabilization of polysomes 
(Spence, Gali et al. 2000), DNA damage conditions (Al-Hakim, Escribano-Diaz et al. 
2010) or SMAD proteins interaction (Dupont, Mamidi et al. 2009). Moreover, Lys63 
chain formation regulates the multivesicular body (MVB) pathway and is 
responsible for the sorting of receptors for endocytosis and their subsequent 
degradation through the endo-lysosomal pathway (Dunn and Hicke 2001, Lauwers, 
Jacob et al. 2009). Lys11 chain represents an independent proteasomal degradation 
signal (Kirkpatrick, Hathaway et al. 2006, Jin, Williamson et al. 2008). Lys27, Lys29 
and Lys33 are instead involved in the clearance of damaged mitochondria (Geisler, 
Holmstrom et al. 2010, Glauser, Sonnay et al. 2011). Lys27 ubiquitylation of Jun and 
Lys29 ubiquitylation of Dexter result in the recruitment of autophagic and/or 
storage vesicles (Chastagner, Israel et al. 2006, Ikeda and Kerppola 2008). Recently, 
Lys27 has been found to trigger the host immune response after microbial DNA 
invasion (Wang, Liu et al. 2014). Instead, Lys33 has been found to be implicated in 
post-Golgi protein trafficking (Yuan, Lee et al. 2014). 
 
UBIQUITYLATION OF PrPC  
Until now, the study of PrPC ubiquitylation has been only focused on PrPC  
degradation by the proteasome. For example, the endoplasmic reticulum associated 
degradation (ERAD) system has been found to be implicated in the ubiquitylation of 
the GSS associated mutant Q217R (Jin, Gu et al. 2000) and of cyPrPC constructs 
(Yedidia, Horonchik et al. 2001). Recently, the ER-associated gp78 E3 ubiquitin 
ligase has been found to ubiquitylate unglycosylated PrPC (Shao, Choe et al. 2014). 
Furthermore, the co-chaperone Stub1 with E3 ubiquitin ligase activity has been 
identified as a PrPC interactor (Gimenez, Richter et al. 2015). All the above evidence 
is focused on the degradation of PrPC. Moreover, the ubiquitin-specific protease 14 
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(USP14), a deubiquitylating enzyme associated to the proteasome that catalyses 
trimming of polyubiquitin chains, has been shown to prevent the degradation of 
both PrPC and PrPSc (Homma, Ishibashi et al. 2015). However, up to now, a defined 
scenario about PrPC ubiquitylation and fate is still missing. 
 
TRAF6 
THE TRAF FAMILY 
The tumor necrosis factor receptor (TNF-R)-associated factor (TRAF) family of 
intracellular proteins were originally identified as signalling adaptors that bind the 
cytoplasmic regions of receptors of the TNF-R superfamily (Inoue, Ishida et al. 2000, 
Wajant, Henkler et al. 2001, Ha, Han et al. 2009). In mammals, the TRAF family is 
composed by six members, with a high degree of similarity. All TRAFs are 
characterized by a C-terminal Ig-like meprin and TRAF homology domain (MATH), a 
coiled coil central domain (CC) and, with the exception of TRAF1, an N-terminal 
RING domain, followed by four zinc-finger motifs (RZF) (Wajant, Henkler et al. 2001, 
Ha, Han et al. 2009, Ostuni, Zanoni et al. 2010) (representative image of TRAF6 is 
shown in Figure 14). The C-terminal and central regions contribute to TRAF 
oligomerization and mediates the interaction with signalling proteins (Chung, Lu et 
al. 2007). The N-terminal domain comprises the core of the ubiquitin catalytic 
domain (Ostuni, Zanoni et al. 2010). Thus, TRAFs function in the regulation of 
signalling both as adaptor proteins and E3 ubiquitin ligases. Further studies have 
revealed TRAFs involvement in the signalling transduction of a variety of other 
receptor families, over than TNF-Rs, including receptors of the innate and adaptive 
immunity and cytokine C-type lectin receptors. The alteration of TRAFs leads to 
autoimmune diseases, cancers and immunodeficiencies (Hildebrand, Yi et al. 2011, 
Namjou, Choi et al. 2012, Netea, Wijmenga et al. 2012). 
46 
 
TRAF6  
TRAF6 is unique among the TRAFs family because of its pleiotropic role in 
participating in the signal transduction of both the TNF-R and the interleukin-1(IL1-
R)/Toll like receptor (TLR) superfamily. many receptor systems (Cao, Xiong et al. 
1996, Lomaga, Yeh et al. 1999, Aderem and Ulevitch 2000, Chung, Park et al. 2002). 
Structurally, dimerization of the RING domain induces higher ordered 
oligomerization of the full TRAF6 protein. The constant shift between dimeric and 
trimeric symmetry of TRAF6 may be a way to facilitate multiple ligand-dependent 
signalling transduction (Yin, Lin et al. 2009). Structural difference of the C-terminal 
domain between TRAF6 and the other TRAFs is responsible of TRAF6 unicity in 
regulating signal transduction in adaptive and innate immunity and bone 
homeostasis (Ye, Arron et al. 2002). 
 
Figure 14. TRAF6 structure. TRAF6 is usually found as a dimer or trimer. In this schematic figure 
TRAF6 trimeric structure in shown. RZF: N-terminal Ring and zinc finger domain; CC: central coiled-
coil region; MATH: C-terminal Ig-like meprin and TRAF homology domain  Adapted from: (Wang, 
Wara-Aswapati et al. 2006).  
 
Genetic ablation of TRAF6 (TRAF6-/-) in mice results in perinatal death, with severe 
osteopetrosis, splenomegaly and thymic atrophy multiple organ abnormalities, 
indicating the essential role of TRAF6 in early development. (Lomaga, Yeh et al. 
1999, Naito, Azuma et al. 1999).  
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TRAF6 IN CELL SIGNALLING 
TRAF6 has been widely shown to act as mediator at the cross-road of diverse cell 
signalling pathways. The classical TLR-dependent activation of NF-κB is regulated by 
the interaction of MyD88 and stimulation of TRAF6 E3 ubiquitin ligase activity. After 
recruitment to signalling rafts, TRAF6 catalyses the attachment of Lys63-linked 
polyubiquitin chains onto its substrates, including itself (Lamothe, Besse et al. 2007, 
Keating and Bowie 2009, Ostuni, Zanoni et al. 2010) and synthesizes free 
unanchored Lys63 chains. TRAF6 functions as a scaffold to activate TAK1, resulting 
in the activation of NF-κB (Xia, Sun et al. 2009). TRAF6 is also involved in the 
signalling down-stream IL-1R/TLR. Upon ligand binding, IL-1R/TLR activate p38 and 
JNK pathways, via TRAF6 and TAK1 (Yamashita, Fatyol et al. 2008). Moreover, 
inhibition of the p38-JNK pathway by p62 and HDAC6 occurs through a negative 
regulation of the signalling complex MyD88-TRAF6 (Into, Inomata et al. 2010). In 
cellular responses to bacterial infection, TRAF6 has been shown to translocate to 
the mitochondria and increase the amount of ROS through ubiquitylation (West, 
Brodsky et al. 2011). During viral infection, the activation of the RIG-1 like receptors 
(RLRs) family of cytosolic RNA helicases triggers the direct binding of TRAF6 to 
mitochondrial antiviral signalling protein (MAVS), which in turn promotes the 
activation of the p-38, JNK and NF-κB (Yoshida, Takaesu et al. 2008, Konno, 
Yamamoto et al. 2009). In the immune response, TRAF6 is also involved in the 
signalling pathways activated by IL-17 receptor (Zhu, Pan et al. 2010), INF receptors 
(Yang, Murti et al. 2005), TGFβ receptor (Wang, McPherson et al. 2012), IL-2 
receptor (Motegi, Shimo et al. 2011). Moreover, TRAF6 is implicated in the 
activation and proliferation of T cells (Bidere, Snow et al. 2006, Xie, Liang et al. 
2013), in the maturation of dendritic cells (Yang, Chen et al. 2008) and in DNA 
damage response (Hinz, Stilmann et al. 2010).  
In the brain, TRAF6 has been demonstrated to interact with NGF-activated TrkA and 
p75NTR receptors (Khursigara, Orlinick et al. 1999, Geetha, Jiang et al. 2005). This 
binding is mediated by p62 (Sanz, Diaz-Meco et al. 2000), after receptor 
dimerization and endocytic internalization (Grimes, Beattie et al. 1997, Riccio, 
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Pierchala et al. 1997). TRAF6 mediated Lys63 polyubiquitylation of TrkA in the 
juxtamembrane region of the receptor results in the activation of the TrkA-MAPK 
signalling (Traverse, Gomez et al. 1992, Yang, Wang et al. 2009). Overexpression of 
TRAF6 mediates activation of PI3K, actin polymerization and growth of long 
filopodia in transfected cells (Wang, Wara-Aswapati et al. 2006). The TRAF6 
recognition sequence (Pro-X-Glu-X-X) binds to Src tyrosine kinase, which in turn 
activates PI3K (Wong, Besser et al. 1999). TRAF6-Src interaction is independent 
from sequestosomes, arguing that the IL1 signalling for actin remodelling results in 
the TRAF6 relocalization in the cytoplasm (Wang, Wara-Aswapati et al. 2006),. 
Although it has been reported that TRAF6 has a cytoplasmic localization before 
activation and translocation to the cell membrane (Force, Glass et al. 2000, 
Hostager, Catlett et al. 2000, Zapata, Pawlowski et al. 2001, Ha, Kwak et al. 2003), 
for some TNFR and TIR, TRAF6 seems to be associated to large membrane-bound 
sequestosomes (Puls, Schmidt et al. 1997, Sanz, Diaz-Meco et al. 2000, 
Seibenhener, Babu et al. 2004).  
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Table 3: Substrates of the E3 ligase activity of TRAF6. Adapted from (Xie 2013). 
 
TRAF6 IN NEURODEGENERATIVE DISEASES 
The first evidence of TRAF6 implication in neurodegeneration was revealed by its 
co-localization with Tau in AD post mortem brains (Babu, Geetha et al. 2005). More 
recently, in AD pathology TRAF6-dependent Lys63 ubiquitylation of presenilin 1 
(PS1) has been found to regulate PS1 function as a passive ER Ca2+ leak channel, 
independently of its γ-secretase activity (Yan, Farrelly et al. 2013). Interestingly, 
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TRAF6 is also involved in the pathogenesis of PD and HD. Indeed, TRAF6 is able to 
promote an atypical ubiquitylation of mutant DJ-1 and α-synuclein in PD and 
huntingtin in HD via Lys6, Lys27 and Lys29, but not with its conventional Lys63 
ubiquitylation. Through ubiquitylation, TRAF6 stimulates the formation of 
aggregates of the disease associated proteins (Zucchelli, Codrich et al. 2010, 
Zucchelli, Marcuzzi et al. 2011). Moreover, TRAF6 is present in post-mortem brains 
of sporadic PD patients (Zucchelli, Codrich et al. 2010).   
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AIM 
Neurodegeneration caused by prions has been extensively studied. However, 
despite various evidence of PrPC involvement in cell physiology, knowledge about its 
physiological function is still lacking. Moreover, confusion surrounding the evidence 
of cytosolic forms of PrPC and the related functions has been increased by the use of 
many different deleted constructs, the cellular type and the animal background 
chosen. Genetic mutations further enrich the scenario in which subpopulations of 
PrPC play a different role in the cell and where the GPI-membrane anchored PrPC is 
able to interact with other PrPC molecules or to mediate cellular signalling. 
In this work, we focus our attention on TRAF6, an E3 ubiquitin ligase known to 
mediate signalling cascades upon receptor triggering. Recent evidence suggests the 
involvement of TRAF6 in the aggregation and atypical ubiquitylation of normal and 
mutated neurodegenerative-associated proteins. We investigated the interplay of 
TRAF6 on PrPC in the context of protein binding, localization and aggregation.  
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CHAPTER 2 
MATERIALS AND METHODS 
CONSTRUCTS  
Wild type (WT) and dominant negative (DN) FLAG and GFP tagged TRAF6 constructs 
and HA-ubiquitin WT were kindly provided by the laboratory of prof. Gustincich 
(SISSA, Trieste, Italy). Full length PrPC (FL PrPC) construct was kindly provided by Dr. 
J.R. Requena (University of Santiago de Compostela, Santiago de Compostela, 
Spain). The cytosolic PrPC 40-231 (cyPrPC) construct was obtained from FL PrPC 
(Giachin, Mai et al. 2015) ). Restriction Free (RF) cloning methodology was used to 
insert a FLAG sequence into the FL PrPC construct between amino acids 40-41, a 
region that does not interfere with the ER translocation sequence and the 
octarepeat region (Figure 1).  
 
 
Figure 1. RF cloning insertion of 2xFLAG sequence into FL PrP
C
 sequence. Different functional 
regions of the PrP
C
 sequence are highlighted. Α-helices and β-sheets are also evidenced. Two-step 
insertion of the FLAG sequence is shown. 
 
2xFLAG sequence insertion was allowed with a two-step RF cloning reaction, in 
order to respect all parameters for a successful cloning procedure (Unger, 
Jacobovitch et al. 2010). The RF procedure is a universal cloning method allowing a 
precise insert of a DNA fragment into any desired position within a circular plasmid.  
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Figure 2. Schematic representation of the restriction-free (RF) cloning. The RF cloning is a two- 
steps process. Initially, the gene of interest is amplified along with primers containing complimentary 
sequences (25-30 bp) to the flanking sites of integration in the target vector. The two strands of the 
PCR product obtained in the first stage are used as mega primers for the second stage of 
amplification. Adapted from (van den Ent and Lowe 2006).  
 
The 2xFLAG sequence (ATGGACTACAAGGACGACGATGACAAG GAATTG 
ATGGACTACAAGGACGACGATGACAAG) was inserted in two steps into the 
pcDNA3.1(-)::MoPrP1-254 construct, between aa 40-41. Primers were designed 
with sequences overlapped to the region chosen for 2xFLAG insertion (Table 2, 
Step1). Reaction of Step 1 was performed as follow:  
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Table 1: Reaction mixture for the insertion of 1xFLAG sequence into pcDNA3.1(-)::MoPrP1-254 
construct. This reaction was repeated for the insertion of the second FLAG sequence into pcDNA3.1(-
)::MoPrP1-254 1xFLAG construct, with the primers indicated in Table2, Step2. 
 
 
Table 2. Primer design for RF cloning insertion of 2xFLAG sequence into wild type FL PrP
C
 
sequence.  
 
The PCR cycle was as follow: Denaturation (95°C 30”), 30x [Denaturation (95°C 30”), 
Annealing (60°C 1’), Elongation (72°C 5’)], Elongation (72°C 7’), Store (4°C ꝏ). Dpn1 
digestion was necessary for the digestion of  the parental DNA template (Dpn1 is 
specific for methylated or hemimethylated DNA) Digestion with DpnI ensures that 
none of the colonies obtained in subsequent transformation contain the parental 
plasmid and therefore reduce the transformation background. Transformation of 
DH5α bacteria was performed as follow with different conditions tested. 
Transformation with 0,5µL of control plasmid, 5µL or 10µL from the PRC reaction. 
After incubation in ice for 20’, transformed bacteria were heat-shocked at 42°C for 
90”. 900 µL of Luria-Bertani (LB) broth (composition for 1L: 10g Bacto-tryptone, 5g 
yeast extract, 10g NaCl. pH 7.5) were added prior to bacterial plating on Amp-
resistant LB plates. Mini-prep of chosen isolated colonies were performed with the 
QIAprep Spin Miniprep kit (27106, QIAGEN). Nanodrop quantification was followed 
by BamH1 digestion, to check for the correct insertion of 1xFLAG sequence into the 
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pcDNA3.1(-)::MoPrP1-254 construct. The procedure described in Step1 was 
repeated for the insertion of the second couple of primers (Table 2, Step2), to 
obtain a 2xFLAG FL PrPC construct. The obtained sequences were sequenced by the 
BMR Genomics. 
A detailed list of utilized construct is found in Table 1 of Results section.  
 
CELL CULTURE 
Human embryonic kidney 293T (HEK293T) cell line was chosen for experimental 
continuity reason with the works of Zucchelli et al. (Zucchelli, Codrich et al. 2010, 
Zucchelli, Marcuzzi et al. 2011). Moreover, HEK293T cells are suitable because they 
do not express endogenous PrPC. Human embryonic kidney (HEK293T) cells were 
cultured at 37°C, 5% CO2 atmosphere in DMEM (Invitrogen) supplemented with 
10% fetal bovine serum (SIGMA). Cells were transiently transfected with the 
amplified DNA constructs listed in Results, Figure 2A with polyethylenimine linear 
(23966,Polysciences) and collected 48 or 72 hours after transfection. 
Mouse neuroblastoma (N2a) cell line wild type for PrPC (WT N2a) and RML infected 
(ScN2a) (Enari, Flechsig et al. 2001) were maintained in culture with MEM (SIGMA), 
supplemented with Glutamax, 10% fetal bovine serum, Non-Essential Amino Acid 
(NEAA). 
 
IMMUNOPRECIPITATION AND WESTERN BLOT 
For co-immunoprecipitation experiments, HEK293T cells were transfected with 
TRAF6 and the indicated PrPC constructs. After transfection, cells were either left 
untreated or incubated for 16 h with 5 µM of the reversible proteasomal inhibitor 
MG132 (C2211, SIGMA) or 10 µM of the irreversible proteasomal inhibitor 
Lactacystin (L6785, SIGMA). 48 hours post transfection was chosen as the best time 
point for co-immunoprecipitation. Cells were lysed in TRAF6 buffer (200 mM NaCl, 
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50 mM Tris pH 7.5, 0.5% NP40, 10% glycerol) supplemented with anti-protease 
inhibitors cocktail (Roche). Cell lysates were incubated for two hours with anti-FLAG 
M2 agarose resin (A2220, SIGMA) or over-night with anti-mouse PrP W226 or anti-
mouse PrP DE10 antibodies followed by two hours incubation with protein A/G 
Sepharose resin (GE Healthcare). Resin was washed with three subsequent 
solutions (Buffer B: 0.01M Tris HCl pH 7.6, 2mM EDTA pH 8.0, 3.5mM NaCl; buffer C: 
0.01M Tris HCl pH 7.6, 2mM EDTA pH 8.0, 12.5mM NaCl, buffer D: 0.01M Tris HCl 
pH 7.6). After washing, proteins were eluted with 2× sodium dodecyl sulfate (SDS) 
Laemli buffer, boiled and processed for standard Western Blot protocol (WB). A 
10% acrylamide gel was used for SDS-PAGE electrophoresis. Proteins were 
transferred on a nitrocellulose membrane. After blocking in 5% milk TBS-T, 
Membranes were blocked with 5% (w/v) milk in 1x Tris buffered saline containing 
0.1% Tween (TBS-T) at room temperature for 1 hour. For GFP detection, blocking 
was performed in 5% (w/v) bovine serum albumin (BSA) in PBS was used. 
Membranes were then incubated over-night with the following antibodies: anti-
rabbit FLAG (1:2000) (F7425, SIGMA), anti-mouse GFP 1:1000 (AB290, Abcam), anti-
human PrP D18 (1:1000), anti-rat β-tubulin (1:1000) (ab6160, Abcam). For 
detection, protein A-HRP (18-160, Millipore), goat anti-mouse HRP (P044701, Dako), 
goat anti-human HRP (11829150, Thermo Scientific) and goat anti-rat HRP (31470, 
Thermo Scientific) conjugated secondary antibodies were used. WB image 
acquisition was performed using the ECL detection kit (Amersham) and the Alliance 
4.7 software (UVITECH).  
 
IN VITRO UBIQUITINATION ASSAY 
HEK293T cells were transfected with HA–Ub, FL PrPC or cy PrPC and FLAG-TRAF6 WT 
or DN constructs. After transfection, cells were incubated with 10 µM MG132 for 3 
h and lysed at 48 hours post transfection with radioimmunoprecipitation assay 
(RIPA) buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1% Triton X-100,1% deoxycholic 
acid and 0.1% SDS) supplemented with anti-protease inhibitors cocktail (Roche). 
Samples were briefly sonicated and centrifuged 10000 rpm for 10min at 4°C. Cell 
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lysates were incubated over-night with anti-mouse PrP W226 antibody. The 
following day, incubation with protein A/G Sepharose resin (GE Healthcare) for two 
hours was performed. Resin was washed with three subsequent solutions (Buffer B: 
0.01M Tris HCl pH 7.6, 2mM EDTA pH 8.0, 3.5mM NaCl; buffer C: 0.01M Tris HCl pH 
7.6, 2mM EDTA pH 8.0, 12.5mM NaCl, buffer D: 0.01M Tris HCl pH 7.6). After 
washing, proteins were eluted with 2× sodium dodecyl sulfate (SDS) Laemli buffer, 
boiled and processed for standard WB protocol, as previously described. Co-
immunoprecipitated ubiquitin was revealed with anti-rabbit HA (1:1000) (71-5500, 
Invitrogen) antibody. The following antibodies were used for WB detection of 
lysates: anti-rabbit FLAG (1:2000) (F7425, SIGMA), anti-human PrP D18 (1:1000), 
anti-rat β-tubulin (1:1000) (ab6160, Abcam). For detection, protein A-HRP (18-160, 
Millipore), anti-human HRP (11829150, Thermo Scientific) and goat anti-rat HRP 
(31470, Thermo Scientific) conjugated secondary antibodies were used. WB image 
acquisition was performed using the ECL detection kit (Amersham) and the Alliance 
4.7 software (UVITECH).  
 
IMMUNOFLUORESCENCE 
Transfected HEK293T cells were cultured on 15mm glass coverslips and fixed in 4% 
paraformaldehyde after 48 or 72 hours. Cells were blocked in 5% NGS (005-000-
121; Jackson ImmunoResearch), 0.3% Triton-X100 in PBS and incubated over-night 
with the following antibodies. For double transfection with cyPrPC and FLAG-TRAF6, 
cells were incubated over-night with anti-mouse PrP (W226) (1:1000) and anti-
rabbit FLAG (1:1000) (F7425, SIGMA) antibodies. Signals were detected with goat 
anti-mouse IgG (H+L) Alexa Fluor 488 (1:500) (A-11001, Life Technologies) and goat 
anti-rabbit IgG (H+L) Alexa Fluor 594 (1:500) (A-11012, Life Technologies) 
fluorescent-conjugated secondary antibodies. For double transfection with FLAG-FL 
PrPC and GFP-TRAF6, incubation with rabbit anti-FLAG (F7425, SIGMA) was 
performed, followed by incubation with goat anti-rabbit IgG (H+L) Alexa Fluor 594 
(1:500) (A-11012, Life Technologies) fluorescent-conjugated secondary antibody. 
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GFP was detected by auto fluorescence at 488 laser. p62 staining on cells 
transfected with FLAG-FL PrPC and GFP-TRAF6 was performed with anti-mouse p62 
antibody (1:500) (610833, BD Transduction Laboratories), followed by incubation 
with goat anti-Mouse IgG (H+L) Biotin antibody (1:100) (SAB4600004, SIGMA) and 
Alexa Fluor® 647 Streptavidin (1:100) (S21347, Life Technologies. For triple 
transfection with FLAG-FL PrPC, GFP-TRAF6 and HA-Ub, cells were incubated with 
anti-mouse FLAG (1:1000) (F3165, SIGMA) and anti-rabbit HA (1:1000) (71-5500, 
Invitrogen) antibodies. Antibody staining was revealed with goat anti-Mouse IgG 
(H+L) Alexa Fluor® 594 conjugate (1:500) (A-11005, Life Technologies) fluorescent-
conjugated secondary antibody and goat anti-Rabbit IgG (H+L) Biotin antibody 
(1:100) (SAB4600006, SIGMA) followed by incubation with Alexa Fluor® 647 
Streptavidin (1:100) (S21347, Life Technologies). GFP was detected by auto 
fluorescence at 488 laser. 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI, 
SIGMA) was used for nuclear staining. N2a cells were fixed in 4% paraformaldehyde, 
treated with 6N guanidine hydrochloride (GdnHCl) for 10 minutes and subjected to 
the protocol described previously. Cells were incubated over-night with anti-mouse 
PrP (W226) (1:1000) and goat anti-rabbit TRAF6 (1:500) (sc7221, Santa Cruz) 
antibodies. Signals were revealed with goat anti-mouse IgG (H+L) Alexa Fluor 488 
(1:500) (A-11001, Life Technologies) and goat anti-rabbit IgG (H+L) Alexa Fluor 594 
(1:500) (A-11012, Life Technologies) fluorescent-conjugated antibodies. Fluorescent 
images (1024x1024 pixels) were acquired with the C1 Nikon confocal with a 40x Oil 
N.A: 1.30 objective, and additionally magnified 4x. 0.7µm steps were chosen for z-
stacks (n. 10-15 per cell). 
 
MICE 
Zurich III wild type PrPC (ZH3 PrP+/+) mice were generously provided by Adriano 
Aguzzi, Institute of Neuropathology, University Hospital of Zurich (Zurich, 
Switzerland) (Nuvolone, Hermann et al. 2016). The colony was maintained ad SISSA 
animal facility (Trieste, Italy). Mice had access to food and water ad libitum and 
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maintained in a 12:12 light:dark cycle with controlled temperature and humidity. All 
experiments employing animals were carried out in accordance with European 
regulations [European Community Council Directive, November 24, 1986 
(86/609/EEC)] and approved by the local authority veterinary service and by the 
Ethics Committee of the Scuola Internazionale Superiore di Studi Avanzati (SISSA), 
Trieste.  
 
CO-IMMUNOPRECIPITATION FROM BRAIN SAMPLES 
ZH3 mice were euthanized with an excess of CO2 and cervical dislocation . Brains 
were extracted and homogenized in modified TRAF6 buffer (150 mM NaCl, 50 mM 
Tris, pH 7.5, 0.5% NP40, 10% glycerol) supplemented with anti-protease inhibitors 
cocktail (Roche), sonicated and centrifuged 10000 rpm for 10min at 4°C. Brain 
lysates were incubated over-night with anti-rabbit TRAF6 antibody (sc7221, Santa 
Cruz) or control IgG (12-370, Millipore), followed by four hours incubation with 
protein A/G Sepharose (GE Healthcare). Resin was washed with three subsequent 
solutions (Buffer B: 0.01M Tris HCl pH 7.6, 2mM EDTA pH 8.0, 3.5mM NaCl; buffer C: 
0.01M Tris HCl pH 7.6, 2mM EDTA pH 8.0, 12.5mM NaCl, buffer D: 0.01M Tris HCl 
pH 7.6). After washing, proteins were eluted with 2× sodium dodecyl sulfate (SDS) 
Laemli buffer, boiled and processed for standard WB protocol, as previously 
described. Proteins were detected on WB with anti-rabbit TRAF6 antibody (sc7221, 
Santa Cruz) followed by incubation with Protein A-HRP (18-160, Millipore) and with 
anti-human PrP (D18) antibody followed by incubation with anti-human HRP 
conjugated antibody. WB image acquisition was performed using the ECL detection 
kit (Amersham) and the Alliance 4.7 software (UVITECH).  
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CHAPTER 3 
RESULTS 
TRAF6 SEQUENCE ANALYSIS 
In this work human TRAF6 WT and DN constructs were used to study the interaction 
with mouse PrPC constructs. The use of human TRAF6 constructs was allowed by the 
high sequence homology (88%) of the human and the mouse TRAF6 sequences. In 
particular the 95% of sequence homology is shared by the C-terminal MATH 
domain, responsible for substrate binding (Figure 1). 
 
Figure 1. Sequence alignment of human and mouse TRAF6 sequences results in 88% of homology.  
TRAF6 N-terminal RING, central Zn-finger and C-terminal TRAF domains are highlighted as in the 
cartoon (95% of sequence homology is shared by the C-terminal MATH (aa 350-499) domain, 80% by 
the RING and Zn-finger domains). 
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CLONING FLAG-PrPC AND CONSTRUCTS 
FL PrPC sequence was cloned with the RF cloning technique for the insertion of a 
2xFLAG sequence at its N-terminal portion. The more suitable region for FLAG 
insertion was identified between aa 40-41. This region does not interfere with the 
signal peptide sequence (aa 1-22), necessary for ER translocation, and the nuclear 
localization sequence (NLS, aa 23-26), as well as with the octapeptide region of PrPC. 
Restriction Free (RF) cloning methodology was chosen for some of its advantages, in 
particular: any vector of choice can be used, there is no need for restriction enzyme 
digestion, cloning can be performed at any desired position and without the 
addition of unwanted extra residues. This universal cloning method allows the 
precise insertion of a DNA fragment into any desired position within a circular 
plasmid. Cloned FLAG-FL PrPC and all the other constructs listed in Figure 2A were 
amplified, sequenced and used for transient transfection in HEK293T cells. Position 
of the FLAG insertion in both TRAF6 and FL PrPC constructs is depicted in Figure 2B.  
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Figure 2. Detailed list of all constructs used in the experiments. A) Description of PrP
C
, TRAF6 and 
ubiquitin constructs used. * This cytosolic form of PrP
C
 (cyPrP
C
) is highly aggregation prone (cytosolic 
puncta) and poorly degraded by the proteasome (Chakrabarti, Rane et al. 2011). In comparison with 
the cytosolic PrP
C
 22-231, rapidly degraded by the proteasome, for its resident time in the cytosol 
this construct is more suitable for the aim of this project. B) Cartoon images of flagged TRAF6 and FL 
PrP
C 
constructs. FLAG was inserted at the N-terminal portion of FL PrP
C
 between aa 40-41. Adapted 
images from (Yin, Lin et al. 2009) and (Burns, Aronoff-Spencer et al. 2003). 
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INTERACTION BETWEEN TRAF6 AND cyPrP 
The aggregation prone neuropathological-associated proteins α-synuclein and 
huntingtin are normally present in the cell cytoplasm (Force, Glass et al. 2000, 
Hostager, Catlett et al. 2000) and are characterized by an intrinsically tendency to 
misfold, a feature exacerbated in presence of protein mutations (Dobson 2001). 
Given the TRAF6 ability to bind the physiological forms of these proteins (Zucchelli, 
Codrich et al. 2010, Zucchelli, Marcuzzi et al. 2011), we decided to investigate its 
interplay with a cytosolic form of PrPC (PrPC 40-231, hereafter named cyPrPC). 
cyPrPC is found in the cytosol in puncta and is less degraded by the proteasome as 
other cytosolic PrPC molecules (Chakrabarti, Rane et al. 2011). In order to assess if 
TRAF6 is able to bind cyPrPC, HEK293T cells were kept in culture and transfected 
with flagged TRAF6 WT (FLAG-TRAF6 WT) and cyPrPC constructs. Cells were left 
untreated or treated with a reversible (MG132) or irreversible (Lactacystin) 
proteasomal inhibitors and lysed after 48 hours from transfection. 
Immunoprecipitation of FLAG-TRAF6 WT (n.=6)  revealed the co-precipitated cyPrPC 
only when the activity of the proteasome was blocked (Figure 3A). To confirm this 
result, we performed a reverse co-immunoprecipitation of HEK293T cells 
transfected with cyPrPC and FLAG-TRAF6 WT, left untreated or treated with 
proteasome inhibitors and lysed as previously described. Immunoprecipitation of 
cyPrPC (n.=2) was performed with two different anti-PrP antibodies: the N-terminal 
anti-PrP DE10 antibody, which recognizes the N-terminal epitope 41-56 (Didonna, 
Venturini et al. 2015), and the C-terminal anti-PrP W226 antibody, mapped at 
epitope: 144-152 of the C-terminal portion of PrPC (Petsch, Muller-Schiffmann et al. 
2011). Immunoprecipitation with the anti-PrP DE10 antibody resulted in the 
detection of the co-immunoprecipitated FLAG-TRAF6 WT. On the contrary, when 
the anti-PrP W226 antibody was used, no co-precipitated FLAG-TRAF6 WT was 
observed (Figure 3B). It is plausible that cyPrPC-TRAF6 WT binding involves the 
cyPrPC C-terminal portion, thus explaining why with the anti-PrP W226 antibody the 
co-precipitated TRAF6 WT is not visible (Figure 3D). A weak cyPrPC-TRAF6 WT 
interaction could explain the loss of TRAF6 binding after the formation of an 
immune complex between the anti-PrP W226 antibody and the PrPC molecule.  
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Figure 3: TRAF6 interacts with cyPrP
C
. A) Direct co-immunoprecipitation of FLAG-TRAF6 WT and 
cyPrP
C
 (n.=6). HEK293T cells were transfected with cyPrP
C
 alone or with FLAG-TRAF6 WT and left 
untreated or incubated with 5µM MG132 or 10µM Lactacystin for 16 h. After 48 hours lysates were 
immunoprecipitated (IP) with anti-FLAG agarose resin and bound proteins were revealed by 
immunoblot (IB) with anti-PrP D18 and anti-FLAG antibodies. Lysates were tested for the expression 
of FLAG-TRAF6 WT and cyPrP
C
 proteins. β-tubulin was used as loading control. B) Reverse co-
immunoprecipitation with cyPrP
C
 and FLAG-TRAF6 WT constructs (n.=2). Experiment was performed 
as in (A) with HEK293T cells treated with MG132 and Lactacystin. Immunoprecipitation was 
performed with the N-terminal anti-PrP DE10 antibody (epitope: 41-56) or with the C-terminal anti-
PrP W226 antibody (epitope: 144-152). Bound proteins were revealed by IB with anti-FLAG and anti-
PrP D18 antibodies. Co-Immunoprecipitation of FLAG-TRAF6 WT was revealed only when the anti-
PrP DE10 antibody was used in IP. C) Cartoon image of FLAG-TRAF6 WT structure showing the 
binding site of anti-FLAG antibody at the N-terminal of the protein. D) Cartoon images showing the 
epitopes of anti-PrP DE10 and W226 antibodies. Anti-PrP DE10 antibody binding did not affect FLAG-
TRAF6 WT binding to cyPrP
C
. On the contrary, anti-PrP W226 antibody binding resulted in a negative 
co-immunoprecipitation result as seen in (B). This led to hypothesise the binding site of FLAG-TRAF6 
WT in the C-terminal portion of cyPrP
C
. 
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TRAF6 CO-LOCALIZE WITH cyPrPC IN DISCRETE 
PERINUCLEAR REGIONS IN AGGRESOME-LIKE 
STRUCTURES 
HEK293T cells were plated and transfected with FLAG-TRAF6 WT and cyPrPC 
constructs. After treatment with 5µM MG132  for 16 hours, cells were fixed at 48 
hours post transfection an stained with anti-FLAG and anti-PrP antibodies. The 
cyPrPC characteristic localization in puncta  (Chakrabarti, Rane et al. 2011) was 
revealed. Staining of FLAG-TRAF6 WT showed a diffused cytoplasmic localization as 
well as the presence of small aggregates in the cytosol and a bigger TRAF6 WT 
aggregate in the perinuclear region.  Partial cyPrPC-FLAG-TRAF6 WT co-localization 
is observed in the perinuclear region (Figure 4).  
 
Figure 4: Co-localization of TRAF6 and cyPrP
C
. HEK293T cells were plated on 15mm coverslips, 
transfected with FLAG-TRAF6 WT and cyPrP
C
 and incubated with 5 µM MG132 for 16 hours before 
fixation at two days in culture. Double-immunofluorescence was performed incubating the cells with 
anti-PrP W226 antibody and FLAG antibody. Overnight primary incubation was revealed with Alexa 
Fluor 488 and 594 conjugated fluorescent secondary antibodies. Nuclei were counterstained with 
DAPI. Merged images reveal the partial co-localization of the FLAG-TRAF6 WT and cyPrP
C 
in the 
perinuclear region (n.=3). Scale bar: 20µm. 
 
cyPrPC IS NOT UBIQUITYLATED 
Given the ability of TRAF6 to ubiquitylate the substrate α-synuclein and huntingtin 
(Zucchelli, Codrich et al. 2010, Zucchelli, Marcuzzi et al. 2011), we decided to 
investigate cyPrPC ubiquitylation, as a consequence of TRAF6 WT binding. Little 
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evidence relative to the ubiquitylation of PrPC is found in literature and its study is 
mostly addressed to proteasomal degradation. HEK293T cells were transfected with 
Ha-Ub, cyPrPC and FLAG-TRAF6 WT and dominant negative (DN). TRAF6 DN retains 
the C-terminal MATH domain for substrate binding but lacks the N-terminal RING 
domain for TRAF6 auto-ubiquitylation and substrate-ubiquitylation. Surprisingly, 
when co-transfected with HA-Ub, cyPrPC is not ubiquitylated, even in absence of 
FLAG TRAF6 WT (n.=3, Figure 5A). This evidence allowed us to postulate the 
localization of the PrPC ubiquitin binding site at the PrPC N-terminal domain 
comprised by aa 1-39. Indeed, three lysine residues are localized in this domain and 
are absent in the cyPrPC construct. In figure 5B a comparison between the full 
length PrPC (FL PrPC, here indicated as PrPC 1-254) and the cyPrPC (indicated as PrPC 
40-231) is shown. Three lysine residues that are present in position 23, 24 and 27 
are absent in the cyPrPC construct. Cartoon images in figure 5C exemplifies the 
putative ubiquitylation of FL PrPC and the lack of ubiquitylation of the cyPrPC 
construct, once established TRAF6 WT binding to the PrPC protein. 
 
Figure 5: lack of cyPrP
C
 ubiquitylation. A) HEK293T cells were transfected with HA-Ub, cyPrP
C
 and 
FLAG-TRAF6 WT or DN constructs, treated with 10µM MG132 for 3 hours and lysed after 48 hours 
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post transfection. Immunoprecipitation (IP) of cyPrP
C
 was performed with anti-PrP W226 antibody. 
The use of W226 was allowed since it does not interfere with PrP-ubiquitin binding. Anti-HA antibody 
was used for HA-Ub detection. No co-precipitated HA-Ub was revealed. Lysates were tested for the 
expression of HA-Ub, cyPrP
C
 and FLAG-TRAF6. β-tubulin was used as loading control. B) Sequence 
analysis of FL PrP
C 
(PrP
C 
1-254) and cyPrP
C 
(PrP
C
 40-231). In blue: Amino acids that are absent in PrP
C
 
40-231 are depicted in blue. Lysine residues are highlighted in yellow. C) Cartoon images showing the 
putative TRAF6 C-terminal binding site to the C-terminal of PrP
C
 and the lysine residues at the N-
terminal of PrP
C
 (23, 24 and 27) that are absent in the cyPrP
C
 construct. Ubiquitin proteins cannot be 
linked to the cyPrP
C
 protein due to the lack of the first N-terminal 1-39 amino acids.  
 
INTERACTION BETWEEN TRAF6 AND FL PrPC 
The evidence of TRAF6 WT-cyPrPC interaction and the absence of cyPrPC 
ubiquitylation, led us to focus our attention to the FL PrPC protein. FL PrPC is 
normally localized to the plasma membrane in lipid rafts, but is also found in 
endosomal vesicles during recycling (Kiachopoulos, Heske et al. 2004) and in a little 
amount in the cell cytoplasm, due to its re-routing from the ER (Kang, Rane et al. 
2006, Orsi, Fioriti et al. 2006). TRAF6 is found in the sub-membrane region of lipid 
rafts, where it is involved in signalling (Lewis and Hooper 2011), besides being 
present in the cytoplasm. In order to verify is TRAF6 WT is also able to bind to the FL 
PrPC,  HEK293T cells were transfected with FLAG-TRAF6 WT and FL PrPC. Cells were 
left untreated or treated with a reversible (MG132) or irreversible (Lactacystin) 
proteasomal inhibitors and lysed after 48 hours from transfection. 
Immunoprecipitation of FLAG-TRAF6 WT (n.=11)  resulted in the detection of co-
precipitated FL PrPC even in absence of proteasomal inhibition. FLAG-TRAF6 WT and 
FL PrPC interaction was enhanced when the activity of the proteasome was blocked 
(Figure 6A). This data is in line with the previous observation of Zucchelli et al., 
where the amount of co-precipitated TRAF6 WT substrate is increased during 
proteasomal inhibition (Zucchelli, Codrich et al. 2010, Zucchelli, Marcuzzi et al. 
2011). To confirm the interaction between FLAG-TRAF6 WT and FL-PrPC and to 
avoid possible artefacts due to the FLAG insertion, reverse co-immunoprecipitation 
was performed. HEK293T cells were transfected with FLAG-FL PrPC and GFP-TRAF6 
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WT and treated as previously described (n.=6, Figure 6B). Immunoprecipitated 
FLAG-FL PrPC was detected with anti-FLAG antibody, while the co-precipitated GFP-
TRAF6 WT was revealed by anti-GFP antibody. Also in this case, the amount of co-
precipitated protein was increased during proteasome inhibition. In figure 6C the 
FLAG epitope recognized by the anti-FLAG antibody at the N-terminal of both FLAG-
TRAF6 and FLAG-FL PrPC constructs  is indicated.  
 
 
Figure 6: TRAF6 interacts with FL PrP
C
. A) Direct co-immunoprecipitation of FLAG-TRAF6 WT and FL 
PrP
C
 (n.=11). HEK293T cells were transfected with FL PrP
C
 alone or with FLAG-TRAF6 WT and left 
untreated or incubated with 5µM MG132 or 10µM Lactacystin for 16 h. After 48 hours lysates were 
immunoprecipitated (IP) with anti-FLAG agarose resin and bound proteins were revealed by 
immunoblot (IB) with anti-PrP D18 and anti-FLAG antibodies. Lysates were tested for the expression 
of FLAG-TRAF6 WT and FL PrP
C
 proteins. β-tubulin was used as loading control. B) Reverse co-
immunoprecipitation with FLAG–FL PrP
C
 and GFP-TRAF6 WT constructs (n.=6). Experiment was 
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performed as in (A) with HEK293T cells treated with MG132 and Lactacystin. Bound proteins were 
revealed by IB with anti-GFP and anti-FLAG antibodies. C) Cartoon images show the inserted FLAG 
sequence in the FLAG-TRAF6 WT and the FLAG-FL PrP
C
 constructs, as the site of immunoprecipitation 
with the FLAG resin.  
 
In order to further validate these data we used an unflagged FL PrPC construct for 
reverse co-immunoprecipitation of HEK293T cells transfected with FL PrPC and 
FLAG-TRAF6 WT. As previously done for immunoprecipitation of cyPrPC, two 
different antibodies for PrPC detection were used. Again, immunoprecipitation of FL 
PrPC resulted in the detection of the co-precipitated FLAG-TRAF6 WT only when the 
N-terminal anti-PrP DE10 antibody was used (n.=3). However, if compared to Figure 
3B, the detected FLAG-TRAF6 WT band after immunoprecipitation with the anti-PrP 
DE10 antibody is lower (Figure 7A). The absence of the co-precipitated substrate 
further confirms the putative binding site of TRAF6 WT to the C-terminal portion of 
PrPC, in a zone that the steric hindrance of protein binding determines the loss of 
protein interaction in favour of the immune binding of the anti-PrP W226 antibody. 
Moreover, the difficulty in detecting a clear band of the co-precipitated FLAG-TRAF6 
WT when the anti-PrP DE10 antibody is used, suggests that the PrPC N-terminal 1-39 
amino acids could influence in its intrinsically flexible nature, the binding of TRAF6 
to PrPC (Figure 7B). Cartoons in figure 7C show the comparison among FL PrPC, 
FLAG-FL PrPC and cy PrPC. Insertion of the FLAG sequence into the FL PrPC molecule 
(between aa 40-41) results in a change in conformation of the N-terminal portion, 
allowing the FLAG antibody not to interfere with PrPC-TRAF6 binding, as observed in 
Figure 6C. Similarly, deletion of amino acids 1-39 at the N-terminal portion of cyPrPC 
has a similar effect of the FLAG insertion into the FL PrPC sequence, thus allowing 
the anti-PrP DE10 antibody to bind to cyPrPC without being an obstacle for cyPrPC-
TRAF6 interaction. 
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Figure 7: Putative influence of the PrP
C
 N-terminal in the TRAF6 WT binging to PrP
C
. A) Reverse co-
immunoprecipitation of unflagged FL PrP
C
 and FLAG-TRAF6 WT revealed a faint band of co-
immunoprecipitated FLAG-TRAF6 WT only when the anti-PrP DE10 antibody is used in 
immunoprecipitation. HEK293T cells were transfected with FLAG-TRAF6 WT alone or with unflagged 
FL PrP
C
 and left untreated or incubated with 5µM MG132 for 16 h. After 48 hours lysates were 
immunoprecipitated (IP) with anti-PrP DE10 antibody (n.=3) or with anti-PrP W226 antibody(n.=6). 
Bound proteins were revealed by immunoblot (IB) with anti-FLAG and anti-PrP D18 antibodies. 
Lysates were tested for the expression of FL PrP
C
 and FLAG-TRAF6 WT proteins. β-tubulin was used 
as loading control. B) Cartoon images show the epitopes recognised by anti-PrP DE10 antibody at the 
N-terminal portion of PrP
C
 and by anti-PrP W226 antibody at the C-terminal portion of FL PrP
C
. C) 
Putative influence of the N-terminal residues 1-39 of PrP
C 
in the TRAF6-PrP
C 
binding. Absence of 1-39 
residues in the cyPrP
C
 or FLAG insertion in the FL PrP
C 
sequences results in a strong detection of co-
precipitated TRAF6 as seen in figure 3B (IP: DE10) and 6B (IP: FLAG). The hardly detectable co-
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precipitated observed in A) (IP: DE10) suggests a role of interference of amino acids 1-39 in the 
TRAF6 binding to FL PrP
C
. 
 
ENDOGENOUS PrPC AND TRAF6 INTERACT IN THE 
MOUSE BRAIN 
Interaction of PrPC and TRAF6 was investigated in the mouse brain. Six month old 
ZH3 PrP+/+ mice brains were lysed an subjected to immunoprecipitation of 
endogenous TRAF6. Interestingly, co-precipitated PrPC was detected, thus 
confirming our in vitro results (n.=3). 
 
Figure 8: PrP
C
 and TRAF6 interacts in the mouse brain. Six month old ZH3 mouse brains were lysed 
with modified TRAF6 buffer and immunoprecipitated (IP) for endogenous TRAF6 (n.=3). WB analysis 
with anti-PrP D18 antibody revealed the presence of co-immunoprecipitated PrP
C 
(Co-IP lane). IgG 
were used as internal control. Lysates were tested for the expression of TRAF6 and PrP
C
. 
  
72 
 
EXPRESSION OF TRAF6 AND FL PrPC AT DIFFERENT 
TIME POINTS 
Various works have suggested the presence of PrPC in the cytosol (Mironov, 
Latawiec et al. 2003, Kang, Rane et al. 2006, Orsi, Fioriti et al. 2006). Our co-
immunoprecipitation data strongly support this evidence for both the cyPrPC and 
the FL PrPC. Prior to evaluate the co-localization of TRAF6 WT and FL PrPC, HEK293T 
cells were single transfected with FLAG-FL PrPC or GFP-TRAF6 WT at two different 
time points (48 and 72 hours) in order to check for possible differences in the 
localization of FLAG-FL PrPC in its trafficking to the membrane as well as changes in 
GPF-TRAF6 WT localization in the cell (n.=2). At 48 hours FLAG-FL PrPC is expressed 
on the cellular membrane and in cellular compartments as at 72 hours post 
transfection (Figure 9A). This data excludes the possibility that at the defined time 
point chosen for immunoprecipitation (48 hours), FLAG-FL PrPC could be present 
only in the cytoplasm, bound to TRAF6. Moreover, it suggests that FLAG insertion 
doesn’t interfere with FL PrPC routing to the membrane. No significant changes 
were observed in GFP-TRAF6 WT localization at the different time points analysed 
(Figure 9B).  
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Figure 9: Expression of FL PrPC and TRAF6. HEK293T cells were transfected with FLAG-FL PrPC (A) or 
GFP-TRAF6 WT (B) and incubated with 5 µM MG132 for 16 hours before fixation at two or three days 
in cultures. Immunofluorescence was performed incubating the cells with anti-FLAG antibody. 
Overnight primary incubation was revealed with Alexa Fluor 594 conjugated fluorescent secondary 
antibody. GFP-TRAF6 WT was revealed by GFP autofluorescence. Nuclei were counterstained with 
DAPI. No differences were observed at the two different time points analysed in the FL PrP
C 
localization: the protein reached the membrane even at 48 hours post transfection. Moreover, it 
showed a cytoplasmic localization. No differences were found in the localization of GFP-TRAF6 as 
diffused in the cytoplasm and present in small aggregates (n.=2). Scale bar: 20µm. 
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TRAF6 CO-LOCALIZE WITH FL PrPC AND IS FOUND IN 
AGGRESOME-LIKE STRUCTURES IN THE PERINUCLEAR 
REGION  
HEK293T cells were plated and co-transfected with FLAG-FL PrPC and GFP-TRAF6 WT 
and fixed at 48 and 72 hours post transfection, after treatment with MG132 
proteasomal inhibitor. Co-localization of FLAG-FL PrPC and GFP-TRAF6 WT into cell 
aggregates was observed at both the two time points analysed. Moreover, a 
different aggregates distribution was visible. Representative images in Figure 10 
show the presence of small well-defined GFP-TRAF6 WT aggregates, some of which 
fully co-localized with FLAG-FL PrPC aggregates. Alternatively, a widespread 
distribution of both proteins was observed, with a co-localization signal into one big 
perinuclear aggregate. Last but not the least, small and diffused aggregates of co-
localizing proteins are found in the cell cytoplasm.  
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Figure 10: Co-localization of TRAF6 and FL PrPC in aggresomes-like structures. Cells were 
transfected with FLAG-FL PrP
C
 and GFP-TRAF6 WT, treated with 5 µM MG132 for 16 hours and fixed 
after 48 hours from transfection. FL PrP
C
 was detected by anti-FLAG antibody followed by incubation 
with Alexa Fluor 594, GFP-TRAF6 WT was revealed by GFP autofluorescence. Nuclei were 
counterstained with DAPI. Merged images revealed protein co-localization into cell aggregates 
independently of the time point chosen. The first panel shows co-localization of FLAG-FL PrP
C
 with 
some small GFP-TRAF6 WT aggregates. The second and third panels show a more diffused staining 
with co-localization of the two proteins into one bigger aggregate. The fourth panel shows co-
localization into small dispersed aggregates (n.=3). Scale bar: 20µm. 
Stack analysis of FLAG-FL PrPC and GFP-TRAF6 WT co-transfected cells revealed 
again the different pattern of aggregates formation. Insight of the representative 
cell in Figure 11A showed the co-localization of FLAG-FL PrPC and GFP-TRAF6 WT 
into small cytoplasmic aggregates and the presence of FLAG-FL PrPC and GFP-TRAF6 
WT aggregates that never co-localize. Two different stacks were chosen to 
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underline that protein co-localization was not due to the merge of all z-stack that 
compose the image. On the contrary, the cell in Figure 11B is characterized by not 
co-localizing FLAG-FL PrPC and GFP-TRAF6 WT aggregates, by two aggregates that 
partially overlap (Figure 1B, white arrow) and by other two aggregates that are in 
close contact but never co-localize (Figure 1B, black arrow). The different 
distribution observed could be explained by the different moment of cell cycle of 
each cell in culture.  
 
Figure 11: Stack analysis of TRAF6 and FL PrP
C
 aggregates. HEK293T cells were co-transfected and 
staining was revealed by immunofluorescence as in Figure 10. A) Co-localization of FLAG-FL PrP
C
 and 
GFP-TRAF6 WT was observed in aggregates in the cell cytoplasm. Some aggregates of  FLAG-FL PrP
C
 
are not positive for GFP-TRAF6 WT and vice versa. Two different z-stacks show the different 
accumulation of aggregates in the cell. B) Aggregates of FLAG-FL PrP
C
 and GFP-TRAF6 WT are 
separate identities in the cell. White arrow: partial overlap of two aggregates. Black arrow: two 
aggregates of FLAG-FL PrP
C
 and GFP-TRAF6 WT in close contact. Scale bar: 20µm.      
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TRAF6 AND FL PrPC AGGREGATES ARE POSITIVE FOR 
THE SEQUESTOSOME MARKER p62 
A way to sequester proteins is represented by accumulation in cellular 
sequestosomes, by the action of p62. The interaction of endogenous TRAF6  with 
substrate receptors is mediated by p62 (Sanz, Diaz-Meco et al. 2000), after receptor 
dimerization and endocytic internalization (Grimes, Beattie et al. 1997, Riccio, 
Pierchala et al. 1997). Moreover, TRAF6 was found associated to large membrane-
bound sequestosomes (Puls, Schmidt et al. 1997, Sanz, Diaz-Meco et al. 2000, 
Seibenhener, Babu et al. 2004). In order to define the nature of FL PrPC and TRAF6 
WT aggregates, HEK293T cells transfected with FLAG-FL PrPC and GFP-TRAF6 WT 
were stained for FLAG-FL PrPC, GFP-TRAF6 WT and endogenous p62. In absence of 
GFP-TRAF6 WT, cytoplasmic FLAG-FL PrPC co-localize with p62. When also the GFP-
TRAF6 WT construct was present, the co-localization was further confirmed in 
aggregates positive for FLAG-FL PrPC, GFP-TRAF6 WT and p62 (Figure 12). From this 
evidence we could assume that the aggregates observed are cellular 
sequestosomes. 
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Figure 12: TRAF6 and FL PrP
C
 co-localize in cellular sequestosomes. HEK293T cells were single or co-
transfected with GFP TRAF6 WT and FLAG-FL PrP
C
 and treated with 5 µM MG132 for 16 hours before 
fixation at 48 hours post transfection. Endogenous p62 was detected by anti-mouse p62 antibody 
followed by biotin-streptavidin 647 conjugated secondary antibody. FLAG-FL PrP
C
 was detected by 
anti-FLAG antibody followed by incubation with Alexa Fluor 594. GFP-TRAF6 WT was revealed by GFP 
autofluorescence. Merged images showed that in absence of GFP-TRAF6 WT, FLAG-FL PrP
C
 is present 
as diffuse staining that co-localize with endogenous p62 in a defined region of the cell. Triple staining 
revealed the co-localization of GFP TRAF6 WT, FLAG-FL PrP
C
 and p62. Increased intracellular staining 
of FL PrP
C
 was observed in presence of GFP TRAF6 WT. Scale bar: 20µm. 
 
FL PrPC IS UBIQUITYLATED EVEN IN ABSENCE OF TRAF6 
In order to verify if TRAF6 WT is able to ubiquitylate the FL PrPC after binding,  
HEK293T cells were transfected with Ha-Ub, FL PrPC and FLAG-TRAF6 WT and DN. 
TRAF6 DN is a perfect internal control, as it excludes artefacts simply due to over-
expression. As previously discussed, TRAF6 ubiquitin ligase activity needs the RING 
domain to ubiquitylated substrate proteins and this domain is absent in the TRAF6 
DN construct. However, we observed the ubiquitylation of  FL PrPC in presence of 
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HA-Ub, independently of TRAF6 expression (Figure 13A). This evidence allowed us 
to confirm the observation on the ubiquitin binding site of the FL PrPC protein. The 
presence of lysine residues in the N-terminal 1-39 portion of the FL PrPC  is 
necessary for ubiquitin binding (Figure 13B). The absence of evident differences 
when FLAG-TRAF6 WT is expressed suggested that other ligases are involved in FL 
PrPC ubiquitylation.  
 
Figure 13: FL PrP
C
 is ubiquitylated. A) HEK293T cells were transfected with HA-Ub, FL PrP
C
 and FLAG-
TRAF6 WT or DN constructs, treated with 10µM MG132 for 3 hours and lysed after 48 hours post 
transfection. Immunoprecipitation (IP) of FL PrP
C
 was performed with anti-PrP W226 antibody. Anti-
HA antibody was used for detection of co-precipitated ubiquitin. Lysates were tested for the 
expression of HA-Ub, FL PrP
C
 and FLAG-TRAF6. β-tubulin was used as loading control. B) The cartoon 
image shows the putative TRAF6 C-terminal binding site and the N-terminal lysine residues that are 
ubiquitylated on the FL PrP
C (n.=4). 
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FL PrPC IS FOUND IN CELLULAR AGGREGATES POSITIVE 
FOR UBIQUITIN AND TRAF6 WT 
Presence of ubiquitin was then investigated in HEK293T cells transfected with Ha-
Ub, FLAG-FL PrPC, and GFP-TRAF6 WT or DN. FLAG-FL PrPC showed a membrane and 
partially cellular localization when expressed alone or with HA-Ub (Figure 14A). 
Addition of GFP-TRAF6 WT resulted in the formation of cellular aggregates of FLAG-
FL PrPC, positive for HA-Ub  and for GFP-TRAF6 WT (Figure 14A-B, inset). As 
magnified in Figure 14B (max stack and two separated z-stacks), smaller aggregates 
positive for FLAG-FL PrPC and HA-Ub (little violet) as well as positive for GFP-TRAF6 
WT and HA-Ub (little blue) were present. No aggregates were observed when TRAF6 
DN was used (Figure 14A). Cell count positive for Ha-Ub, FLAG-FL PrPC and GFP-
TRAF6 WT revealed that the 59% of cells contained aggregates of HA-Ub and GFP-
TRAF6 WT were negative for FL PrPC, that maintained prevalently a membrane 
localization. The remaining 41% was characterized by aggregates positive also for FL 
PrPC (n. cell counted= 128, from two different experiments). 
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Figure 14: TRAF6 WT promotes the accumulation of FL PrP
C
 in cellular aggregates A) Cells were 
single transfected with FLAG-FL PrP
C
 or in combination with HA-Ub or HA-Ub and GFP-TRAF6, treated 
with 5 µM MG132 for 16 hours and fixed after 48 hours from transfection. Double 
immunofluorescence was performed with anti-FLAG and anti-HA antibodies followed by incubation 
with Alexa Fluor 594 and biotin-streptavidin 647 conjugated secondary antibodies. GFP-TRAF6 was 
revealed by GFP autofluorescence. In presence of GFP-TRAF6 WT, FLAG-FL PrP
C
 was found in cellular 
aggregates positive for TRAF6 and ubiquitin. This was not observed when GFP-TRAF6 DN was 
expressed. B) Inset of FLAG FL PrP
C
 aggregates in presence of HA-Ub and GFP-TRAF6 WT from panel 
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A. Partial triple co-localization (white) was observed (max stack and Stack 19). Smaller GFP-TRAF6 
WT and HA-Ub positive aggregates (little blue) surrounded a core of FLAG-FL PrP
C
 (red), clearly 
visible in Stack 02. FLAG-FL PrP
C 
and HA--Ub aggregates (little violet) are present throughout the cell 
(n.=2). 
 
PrPC AND TRAF6 CO-LOCALIZATION IN THE N2a CELL 
MODEL 
Murine N2a cells were used as a second in vitro model to study the interplay 
between TRAF6 and PrPC. These cells are frequently used for the investigation of 
the pathological form of PrP (PrPSc), since infected with the RML strain of prion. The 
use of this cell model would give a validation of the over-expression system used 
with HEK293T cells and a first pathological evidence of the interplay of TRAF6 and 
PrPC. We first checked for endogenous TRAF6 expression in N2a cells, knock-out for 
PrPC expression (KO N2a), expressing the wild type PrPC  (WT N2a) or its pathological 
form (ScN2a). Cells were plated and fixed after 48 hours in culture. Protein 
expression was revealed after staining with anti-PrP W226 and anti-TRAF6 
antibodies. TRAF6 was endogenously expressed in N2a cells (Figure 15, upper 
panel). Co-localization of PrPC and TRAF6 was observed in WT N2a cells as diffused 
staining, and clearly detected in ScN2a cells. ScN2a cells were characterized by 
aggregates of both PrPSc and TRAF6 that showed a certain degree of co-localization. 
Not all the ScN2a cells showed an increased PrP expression and accumulation. In 
these cells, also the TRAF6 staining revealed a diffused and not aggregated 
localization, similar to the one observed in WT N2a cells (Figure 15B, inset).  This 
data suggests a tendency of endogenous TRAF6 to aggregate in presence of PrPSc.  
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Figure 15: PrP
C
 and TRAF6 expression and localization in N2a cells. A) N2a cells were fixed after 48 
hours in culture and treated with GdnHCl for 10 minutes. Double immunofluorescence was 
performed with anti TRAF6 and W226 anti-PrP antibodies, followed by incubation with secondary 
Alexa Fluor 594 and 488 antibodies. Nuclei were counterstained with DAPI. N2a cells were positive 
for TRAF6. Co-localization of PrP and TRAF6 was clearly seen only in ScN2a cells (n.=2). Scale bar: 
10µm. B) Zoom-in images from panel (A) revealed a variable pattern of co-localization. 
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CHAPTER 4 
DISCUSSION 
Great attention has been addressed to the study of the pathological isoform of PrPC 
until the discovery of being the causative agent of transmissible encephalopathy 
(Prusiner 1991). Indeed, investigation of the mechanisms of aggregation and 
spreading has added a conspicuous  amount of information to the field. However, a 
complete knowledge about PrPC physiological functions is still lacking. Evidence 
suggests a role for PrPC as a receptor involved in intracellular signalling for neuronal 
development (Gauczynski, Peyrin et al. 2001, Schmitt-Ulms, Legname et al. 2001), 
(Zanata, Lopes et al. 2002, Chen, Mange et al. 2003, Kanaani, Prusiner et al. 2005, 
Santuccione, Sytnyk et al. 2005) and signalling transfer from cell to cell (Liu, Li et al. 
2002). Moreover, neuronal survival has been observed due to PrPC interaction with 
Grb2 in the endosomal compartment (Spielhaupter and Schatzl 2001). An increased 
number of evidence point to an anti-apoptotic function of PrPC correlated to its 
presence in the cytosol (Deckwerth, Elliott et al. 1996, Kuwahara, Takeuchi et al. 
1999, Roucou, Guo et al. 2003, Roucou, Giannopoulos et al. 2005). However, 
opposing results were obtained when different models and different cytoplasmic 
PrPC constructs were used (Ma and Lindquist 2001, Yedidia, Horonchik et al. 2001, 
Ma, Wollmann et al. 2002, Paitel, Fahraeus et al. 2003). In order to clarify this 
uncertain scenario, Hegde and colleagues demonstrated that, in the processing of 
PrPC, a small percentage of the protein fails to enter into the ER or is 
retrotranslocated from the ER into the cytoplasm, where it can exert its protective 
function prior to be degraded. Pathological point mutations also results in 
cytoplasmic residence of PrPC (Hegde and Lingappa 1999, Kim and Hegde 2002). This 
cytoplasmic PrPC population is targeted by the UPS for proteasomal degradation 
(Jin, Gu et al. 2000, Lee, Iwakoshi et al. 2003, Shao, Choe et al. 2014) and shouldn’t 
be confused with PrPC endocytosed from and recycled to the cell membrane or 
degraded by the autophagic system. Autophagy of PrP has been investigated for its 
pathological relevance in presence of PrPSc (Boellaard, Kao et al. 1991, Sikorska, 
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Liberski et al. 2004, Heiseke, Aguib et al. 2010, Liberski, Sikorska et al. 2010, Yao, 
Zhao et al. 2013). PrPSc aggregates are found in infected cells and degraded by p62-
mediated degradation (Homma, Ishibashi et al. 2014). Instead, cytotoxic form of 
cytosolic PrP constructs are present in dispersed aggregates, that do not share 
characteristic features of aggresomes (Beaudoin, Goggin et al. 2008). Further 
investigation of the cellular mechanisms involved in the processing of both 
physiological and pathological isoforms of PrPC is necessary. 
In this work we focus our attention to the TRAF6 protein. TRAF6 is involved in the 
regulation of signalling both as an adaptor protein and as an E3 ubiquitin ligase. Its 
atypical substrate ubiquitylation viaLys63 was deeply investigated in the activation 
and signalling of NF-κB (Xia, Sun et al. 2009). This led to address to TRAF6 a principal 
role in the inflammatory and immune responses. Moreover, involvement of TRAF6 
Lys63 atypical ubiquitylation in actin polymerization and cytoskeletal 
rearrangement was also observed (Wang, Wara-Aswapati et al. 2006). A role for 
TRAF6 in protein aggregates formation was also hypothesized. Indeed, TRAF6 was 
found in aggregates of Tau protein in AD (Babu, Geetha et al. 2005) and of α-
synuclein in sporadic PD (Zucchelli, Codrich et al. 2010) post-mortem brains. 
Interestingly, the investigation of TRAF6 binding and ubiquitylation of substrate α-
synuclein and huntingtin revealed a different ubiquitylation code, in which Lys6, 
Lys27 and Lys29 are involved (Zucchelli, Codrich et al. 2010, Zucchelli, Marcuzzi et 
al. 2011). Aggregates formation in presence of TRAF6 ubiquitylation activity was 
observed for both the pathological and the physiological α-synuclein and huntingtin 
proteins (Zucchelli, Codrich et al. 2010, Zucchelli, Marcuzzi et al. 2011). In this work, 
we analysed the interplay of TRAF6 with the physiological form of PrPC, in order to 
unveil a common cellular response to naturally aggregation-prone proteins.  
We found that TRAF6 and PrPC interact when co-expressed in vitro. We used a FL-
PrPC (mouse, aa 1-253) construct in order to mimic the physiological PrPC and a 
cyPrPC (mouse, aa 40-231), that is not processed as the FL-PrPC and resides in the 
cytosol in puncta. This cytosolic form of PrPC is not rapidly degraded by the 
proteasome (Chakrabarti, Rane et al. 2011). The use of this two constructs was 
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justified by the cytosolic localization of TRAF6 (Force, Glass et al. 2000, Hostager, 
Catlett et al. 2000). At first we expected a positive immunoprecipitation result only 
in case of cyPrPC. Indeed, co-immunoprecipitation of cyPrPC was observed after 
immunoprecipitation of FLAG-TRAF6. cyPrPC-TRAF6 interaction was further 
increased under condition of transient and irreversible proteasomal inhibition 
(Figure 3A). The reverse co-immunoprecipitation was positive only when an N-
terminal PrP antibody was used (DE10, epitope: 41-56). Reasonably, the interaction 
of the C-terminal portion of TRAF6 (substrate binding domain) and PrPC involves the 
C-terminal PrP domain. The formation of the immune complex between PrP and the 
C-terminal PrP W226 antibody (epitope: 144-152) undermines the PrPC-TRAF6 
binding and results in a negative co-immunoprecipitation result (Figure 3B). 
Surprisingly, PrPC-TRAF6 interaction was also observed when the FL-PrPC construct 
was used. Direct co-immunoprecipitation using flagged TRAF6 and FL PrPC was 
confirmed by reverse co-immunoprecipitation of GFP-tagged TRAF6 and flagged FL 
PrPC. PrPC-TRAF6 interaction was further increased under condition of transient and 
irreversible proteasomal inhibition (Figure 6). Also in this case, immunoprecipitation 
of an unflagged FL PrPC construct results in the negative co-immunoprecipitation of 
TRAF6 when the W226 antibody was used. A positive even if faint result was 
obtained with the DE10 antibody (Figure 7A). This data confirms the previous 
evidence for the site of PrPC-TRAF6 interaction and suggests that the truncation of 
aa 1-39 as well as the insertion of a FLAG sequence between aa 40-41 of PrPC allows 
the detection of PrPC-TRAF6 interaction. In this model, we can assume that the very 
first part of the PrPC N-terminal flexible domain is not involved in the interaction 
and that the FLAG insertion modifies the structure in the way of a more open 
conformation to allow protein binding and formation of the immune complex with 
anti-FLAG antibody.  
It could be argued that the interaction observed with the FL PrPC is the result of an 
artefact due to overexpression of the construct and subsequent accumulation in the 
cell cytosol, where it can interact with TRAF6. Probably, the amount of FL PrPC in 
the cytosol is increased in our cellular model, allowing us to investigate an effect 
that physiologically is probably strictly kept under control. The presence of all 
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glycosylated isoform of PrPC in western blot and the correct membrane localization 
(Figure 9A) of FL PrPC construct suggests that its cytosolic localization could be the 
result of recycling from the cell membrane. However, we can also assume that a 
portion of FL PrPC originates from ER retro-translocation. It is more plausible that 
free cytosolic FL-PrPC rather than vesicle-contained FL PrPC interacts with TRAF6, 
even if a sub-membrane localization of TRAF6 has been demonstrated for TRAF6 
signalling recruitment to lipid rafts (Inoue, Ishida et al. 2000, Wajant, Henkler et al. 
2001, Lamothe, Besse et al. 2007, Ha, Han et al. 2009, Xia, Sun et al. 2009). 
Involvment of TRAF6 in the internalization of FL PrPC, normally associated to lipid 
rafts (Vey, Pilkuhn et al. 1996) should not be excluded. To validate our in vitro 
results, co-immunoprecipitation of PrPC and TRAF6 was observed in the mouse brain 
at six month of age. We chose this time point hipothesising that in the brain of a 
mature aged mouse the UPS system is not perfect as in early stage of life. In fact, at 
two months of age we observed contrasting results (data not shown). It is curious to 
note that the endogenous PrPC co-precipitated prevalently in its diglycosilated 
isoform.  
Immunofluorescence experiments revealed PrPC-TRAF6 co-localization. 
Overexpression of cyPrPC and TRAF6 resulted in the formation of small aggregates 
of cyPrPC that partially co-localized with bigger TRAF6 aggregates (Figure 4). 
Moreover, a clear co-localization was observed when FL PrPC was co-transfected 
with TRAF6 (Figure 10). Interestingly, despite the time point chosen, we observed 
different type of aggregation of FL PrPC and TRAF6: small co-localizing aggregates or 
amorphous bigger co-localizing aggregates of FL PrPC and TRAF6 are observed in 
(Figure 10). However, we also observed partial co-localization or total absence of 
co-localization of FL PrPC and TRAF6 aggregates that could be in close contact or in 
separated cytosolic domains (Figure 11). We can hypothesize that TRAF6 is in some 
extent responsible for PrPC aggregation. Alternatively, TRAF6 could be involved in 
the accumulation of FL PrPC aggregates in the cytosolic compartment providing an 
inert stock of molecules or marking them for autophagic degradation. This is in line 
with the ability of TRAF6 to promote an atypical ubiquitylation of the substrate 
proteins and with its interaction with p62 (Sanz, Diaz-Meco et al. 2000). 
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Furthermore, our data are in line with the demonstrated interaction and aggregate 
localization of TRAF6 with α-synuclein and huntingtin (Zucchelli, Codrich et al. 2010, 
Zucchelli, Marcuzzi et al. 2011). It is interesting to note a parallelism among α-
synuclein, huntingtin and the prion protein, despite the cellular localization. The 
natural tendency of these proteins to misfold is increased in presence of mutations 
that affect protein structure. Moreover, presence of a respective “seed” or fibrillar 
substrate enhance the misfolding process. All togheter, this evidence strongly 
supports a common role for TRAF6 in aggregate formations of these 
neurodegenerative-associated proteins, suggesting a control mechanism at first in 
the processing of their physiological forms.   
Interestingly, we found a co-localization of PrPC and TRAF6 with the sequestosomes 
marker p62 (Figure 12). In sequestosomes, polyubiquitylated proteins are 
sequestered prior to be degraded by the autophagolysosomal pathway (Bjorkoy, 
Lamark et al. 2005, Komatsu, Waguri et al. 2007, Pankiv, Clausen et al. 2007, 
Ichimura, Kumanomidou et al. 2008) or linked to the proteasome (Seibenhener, 
Babu et al. 2004). Moreover, as mentioned before, TRAF6 is able to interact with 
p62 (Sanz, Diaz-Meco et al. 2000) and associates to large membrane-bound 
sequestosomes during activation of TNFR and TIR receptors (Puls, Schmidt et al. 
1997, Sanz, Diaz-Meco et al. 2000, Seibenhener, Babu et al. 2004). Our result 
suggests that PrPC and TRAF6 aggregate in sequestosomes. This data is supported 
by the evidence of a co-localization of FL PrPC and TRAF6 WT with ubiquitin in 
cellular aggregates (Figure 14B). We found that FL PrPC is ubiquitylated in presence 
of TRAF6 WT. FL PrPC ubiquitylation was not observed in absence of TRAF6 or when 
the ligase-incompetent TRAF6 DN was expressed. Only the 41% of the cells 
analysed, transfected with all three constructs, contined aggregates positive for FL 
PrPC, TRAF6 WT and HA-Ub. In the remaining 59% aggregates were positive only for 
TRAF6 WT and HA-Ub (Figure 14). A representative image in Figure 14B shows the 
combination of staining that could be observed with the transfected proteins. FL 
PrPC ubiquitylation is in line with previous works focused on the role of PrPC 
ubiquitylation and proteasomal degradation for cytosolic forms of PrPC (Shao, Choe 
et al. 2014), GSS-related cytosolic PrPC mutants (Jin, Gu et al. 2000) and 
89 
 
unglycosilated PrPC constructs (Zhang, Wang et al. 2012). Co-localization of TRAF6 
WT and ubiquitin is justified by TRAF6 auto-ubiquitylation activity after 
oligomerization (Ostuni, Zanoni et al. 2010). The fact that less than the half of the 
analysed cells contain FL PrPC-ubiquitin aggregates also positive for TRAF6 WT leads 
us to speculate that TRAF6 has a specific role in PrPC ubiquitylation and it involves 
the formation of PrPC positive sequestosomes. This evidence is further supported by 
the ubiquitylation assay result. Also in absence of TRAF6 or in presence of the 
ligase-incompetent TRAF6 DN, the FL  PrPC is ubiquitylated (Figure 13A). It should be 
interesting to investigate the code of atypical ubiquitylation involved in the TRAF6 
ubiquitylation of FL PrPC. We can postulate a Lys6, Lys27 and Lys29 atypical 
ubiquitylation as for α-synuclein, DJ-1 and huntingtin (Zucchelli, Codrich et al. 2010, 
Zucchelli, Marcuzzi et al. 2011), rather than the Lys63 dependent ubiquitylation 
observed e.g in the NF-κB pathway (Lamothe, Besse et al. 2007, Keating and Bowie 
2009, Ostuni, Zanoni et al. 2010). However, Lys63 dependent FL PrPC ubiquitylation 
should not be excluded taking into account the role of PrPC in cellular signalling 
(Mouillet-Richard, Ermonval et al. 2000, Schmitt-Ulms, Legname et al. 2001, 
Kanaani, Prusiner et al. 2005). Further analysis should be done to clarify if TRAF6 
WT could in some way influence the amount of FL PrPC in the cytosol. In presence of 
the ligase-incompetent TRAF6 DN, as well as when TRAF6 is not expressed, FL PrPC 
seems to be localized prevalently on the cellular membrane and is not present in 
cytosolic aggregates (Figure 14A). Moreover, we have observed an increased FL PrPC 
expression in HEK293T cells when co-transfected with TRAF6 WT, if compared to 
cells only transfected with FL PrPC (data not shown).  
We have further identified the putative ubiquitin PrPC binding site. Ubiquitylation of 
cyPrPC was not observed nor in presence neither in absence of TRAF6. Deletion of 
amino acids 1-39 in the cyPrPC construct results in the lost of Lys23, Lys24 and 
Lys27. It is reasonable that one of this three lysine residues present in the first part 
of the N-terminal of PrPC is the substrate of ubiquitylation.  
N2a cells were used to investigate PrP-TRAF6 interaction in another cell line model. 
N2a cells that expresse the endogenous PrPC do not show a clear co-localization 
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result. This is in line with the hypothesis that in physiological condition and in a not 
overexpressing system the amount of cytosolic resident PrP is low. However, the 
expression of the pathological PrPSc results in formation of TRAF6 aggregates that 
partially co-localize or are in proximity of PrPSc aggregates (Figure 15). This data 
suggests the involvement of TRAF6 in the aggregation of pathological PrPSc and 
gives further light to a common cellular response to neurodegenerative-associated 
proteins.  
In order to confirm the data on N2aSc cells, PrP-TRAF6 interaction should be 
analized in vivo on RML infected mouse brains. This data would be a further 
evidence for TRAF6 involvement in pathological conditions, as seen for the presence 
of TRAF6 in Tau-containing intracellular aggregates in AD post-mortem brains 
(Babu, Geetha et al. 2005) and in Lewy bodies in DA neurons of PD post-mortem 
brains (Zucchelli, Codrich et al. 2010).  
In this work we have highlighted the involvement of TRAF6 in the targeting, 
aggregation and ubiquitylation of cytosolic and full length PrPC. The interaction in 
vivo further confirms our data. Moreover, our in vitro evidence of a co-localization 
of aggregated forms of PrPSc and TRAF6 allow us to postulate a common mechanism 
in the cellular response to neurodegeneration.   
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